Ivermectin and Mebendazole for Cancer: 700+ Public Case Reports (August 2026 Edition)

-

Introduction

Ivermectin is an antiparasitic drug widely recognized—second only to penicillin—for having one of the greatest impacts on human health. Its discovery was honored with the Nobel Prize in 2015, reflecting its profound significance. Originally developed to treat parasitic infections such as river blindness (onchocerciasis) and intestinal strongyloidiasis, ivermectin’s list of medical indications has expanded due to its notable antiviral and anti-inflammatory properties. It is also included on the WHO’s Model List of Essential Medicines. 

Several studies reported antiviral effects of ivermectin on RNA viruses such as dengue, Zika, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and COVID 19 virus.

More recently, ivermectin has garnered attention for its potential role in cancer treatment, particularly in advanced stages where conventional therapies often fall short. This article compiles over 130 case reports, featuring remarkable instances of Stage 4 cancer patients achieving significant tumor regression or even "No Evidence of Disease" (NED) status after integrating ivermectin into their treatment protocols. Although most existing studies remain preclinical and large-scale clinical trials are still lacking, these real-world cases suggest that ivermectin—often combined with other repurposed antiparasitic drugs like fenbendazole—may improve outcomes in cancers traditionally considered incurable.

For completeness, we have also included cancer case studies involving other antiparasitic agents such as fenbendazole and mebendazole. This comprehensive resource aims to support further research and facilitate informed discussions between patients and healthcare professionals about innovative cancer therapies.

Ivermectin and Fenbendazole for cancer

Ivermectin and Cancer

Ivermectin and its potential role in cancer treatment have sparked significant interest online. Through our research, we've observed that most studies available are preclinical, with a notable lack of published clinical studies. To assist with further investigation, we have compiled and categorized case reports by cancer type in one place.

Typically, when one adds ivermectin to standard cancer treatment, they might improve their outcome, meaning that the tumor shrinks faster or their cancer biomarkers, such as PSA, CA 125, or CEA drop.

When this occurs in Stage 1, 2, or 3 cancers, it is sometimes difficult to tell whether it was the standard treatment, that is the surgery, chemotherapy, radiation or immunotherapy that produced the benefit. However, when the cancer has progressed to Stage 4, and particularly when it involves one of the often-incurable cancers such as the types in the below table under the “Palliation Only (Metastatic)” category where standard chemotherapy is largely ineffective, it becomes obvious that the repurposed drug made the difference.

Table Courtesy of Dr. Marik and Cancer Care

Read some of the stage 4 cancer case reports below. Some achieved NED - the remarkable category of “No Evidence of Disease” where their scans showed no more evidence of cancer. When this occurs in metastatic cancer, it is tantamount to a miracle for those patients and their families.

This collection serves as a resource for researchers and those exploring Ivermectin's potential applications. However, it's vital to consult with qualified medical professionals regarding any treatment decisions.

While conventional medical professionals often regard case reports as anecdotal or lower-quality evidence, they generally prioritize large, double-blinded, randomized placebo-controlled trials (RCTs) as the gold standard. We acknowledge that RCTs provide stronger evidence. 

Still, the potential benefits of Ivermectin, coupled with its comparatively low risk profile and cost, warrant serious consideration and further exploration.

Below is the list categorised by different cancer types, alphabetically.

Summary:
  • Editor's Preface
  • Introduction
  • Ivermectin, Mebendazole and Fenbendazole Case Series Compilation (alphabetical)
    1. Breast Cancer Success Stories (128 cases)
    2. Brain Cancer (including Glioblastoma) (135 cases)
    3. Bladder Cancer Success Stories (including kidney cancer) (36 cases)
    4. Cervical Cancer (6 cases)
    5. Colorectal Cancer (including Appendix cancer) (85 cases)
    6. Esophageal and Stomach cancer (23 cases)
    7. Endometrial Cancer (13 cases)
    8. Gastric (Stomach) cancer (see Esophageal and Stomach Cancer) 
    9. Head and Neck Cancer (17 cases)
    10. Kidney Cancer Case Series (including urinary (urothelial) bladder cancer)
    11. Liver and Bile Duct Cancer (Hepato-biliary system) (9 cases)
    12. Lung Cancer (55 cases)
    13. Leukemia (13 cases)
    14. Lymphoma (28 cases)
    15. Melanoma (refer to Skin Cancer)
    16. Multiple Myeloma (8 cases)
    17. Myelodysplastic Syndrome
    18. Oral Cancer (refer to Head and Neck)
    19. Ovarian Cancer (17 cases)
    20. Pancreatic Cancer (47 cases)
    21. Prostate Cancer (128 cases)
    22. Sarcoma (8 cases)
    23. Skin Cancer (16 cases)
    24. Throat Cancer (refer to 'Head and Neck')
    25. Thymus cancer (2 cases)
    26. Thyroid Cancer (4 cases)
    27. Turbo Cancer (Aggressive Cancer)
    28. Testicular Cancer
    29. Uterine cancer (refer to Endometrial Cancer above) (7 cases)
    30. Others
  • Discussion
  • Conclusion
Source: X.com

Fenbendazole Cancer Success Stories

Editor's Preface

Introduction: From a Handful to Hundreds

The mission of this compilation is to inspire and support patients facing similar challenges, particularly those who feel abandoned, overlooked, or underserved in their medical journey. What began as a small collection of individual case reports (unique, experience-based, non-commodity content) has evolved into a repository of more than 700 patient stories—each reflecting resilience, hope, determination, and lived experience.

This resource brings together publicly available reports, case series, testimonials, and studies involving ivermectin, fenbendazole, and other related repurposed therapies in cancer care. Sources include social media platforms, online patient communities, independent websites, published case reports, peer-reviewed case series, and clinical studies. Visitors can explore the compilation by cancer type and review the number of currently documented patient- and physician-reported outcomes.

The purpose of this compilation is not to establish efficacy or replace professional medical advice, but to preserve and organize patient experiences that may otherwise be difficult to find. Many of these accounts represent real-world experiences that are unlikely to receive attention from large mainstream media organizations or major academic institutions.

Presented in a raw or lightly edited format, these stories offer insight into the diverse paths patients take when navigating cancer. Whether viewed as anecdotal evidence, hypothesis-generating observations, or personal testimonies, they serve as a reminder that patients are not alone in their journey. Shared experiences can provide perspective, encouragement, and a sense of community during some of life's most difficult moments.

Cancer remains a leading cause of global morbidity and mortality, with advanced-stage (stage IV) disease associated with poor prognosis. In recent years, the anti-parasitic agents ivermectin, fenbendazole, and mebendazole have attracted interest for their potential anticancer properties based on preclinical and mechanistic studies. However, in the absence of robust randomized controlled trials (RCTs), these approaches remain outside mainstream oncology practice. A growing number of case reports and anecdotal accounts—numbering in the hundreds—describe heterogeneous responses across multiple cancer types, to address the knowledge gap. Such observations, while hypothesis-generating, are rarely published in major medical journals and require careful interpretation.

While these anecdotal reports—supported by PET scan evidence and the surprise expressed by oncologists—signal a potential paradigm shift in cancer management, they remain observational at this stage. Robust, long-term clinical trials are necessary to confirm their efficacy, safety, and how best to incorporate them into mainstream treatment protocols. However, it’s important to recognize that it may take years before these anti-cancer agents are accepted in leading medical journals, as groundbreaking results often face strong resistance. The true validation may come not from top-tier publications, but from a grassroots movement of empowered patients and doctors demonstrating proven results.

The story from 1929 exemplifies how unexpected discoveries can change scientific paradigms. Alexander Fleming returned from vacation to find a strange mold on his agar plates that inhibited bacterial growth. He published his findings here (PubMed) in 1929, but initially, it received little attention. The scientific world largely ignored this for a decade, until the publication of this article (Lancet) in 1940 and the discovery of clinical usage of Penicillin ushered in the age of antibiotics. 

It is heartbreaking to know that millions of people around the world face cancer each year—often feeling overwhelmed, frightened, and searching desperately for answers. Too many families are left navigating complex medical information with limited time and few clear options.

That reality is what drove us to begin this work. We have spent countless hours researching, reading, and reviewing both conventional treatments and lesser-known approaches that may not always receive mainstream attention. Along the way, we discovered something powerful: many patients and caregivers are actively sharing their stories, experiences, and lessons learned. These voices deserve to be heard.

So we made a commitment—to gather as many relevant case studies, references, and insights as possible in one place, so that others do not have to search alone.

Our mission is simple: to make information accessible, transparent, and freely available to anyone who needs it. There is no paywall. No gatekeeping. Just open access to research and shared experiences from around the world.

To sustain this platform and continue expanding our work, we may receive a small commission from certain related links—only if you choose to purchase through them, and always at no extra cost to you. Your trust matters to us, and transparency will always remain a priority.

If even one person feels more informed, more empowered, or less alone because of this guide, then this effort has been worthwhile.

We have compiled unadulterated stories relating to anti-parasitic drugs and cancer—events so unprecedented that they challenge conventional perceptions of reality and may signal a paradigm shift in cancer treatment.

The Conventional Perspective on Cancer Treatments

Before addressing inflammatory claims in mainstream fact-checking articles and the 'misinformation' labels applied by social media platforms, let’s explore the conventional perspective on cancer, as typically presented by medical specialists and major media outlets:
  • We need larger, high-quality studies before making formal recommendations.
  • This is medical misinformation! There is no evidence that fenbendazole works, or its effectiveness is not scientifically proven.
  • Case series are 'anecdotals' (not necessarily true or reliable; weak evidence). There are no randomized controlled trials* on fenbendazole and cancer in humans.
  • This is ‘false hope.’ If something sounds too good to be true, it probably is.

*RCT methods are 50+ years old... RCT (Randomised Controlled Trial) is a form of scientific experiment used to control factors not under direct experimental control. RCT is considered the 'gold standard' for human research. RCTs were recognised as the standard method in the 20th century. First 'blind experiment' was in 1784 and first published RCT was in 1948 (Wikipedia). The Randomised placebo Controlled Trial (RCT) method for hard evidence is a very expensive and impractical model when it comes to something as complicated as cancer. Most drugs are designed to affect one part of cancer and not the other parts of cancer or even the root causes of cancer. To understand more of this concept, check out 'hallmarks of cancer'. The randomized placebo-controlled trial (RCT)* is widely regarded as the gold standard for generating high-quality evidence in medicine. However, when it comes to cancer, the RCT model is often prohibitively expensive, time-consuming, and sometimes impractical. See "Randomised controlled trials (RCTs), are often costly, slow, and logistically challenging - ChatGPT". RCTs typically focus on evaluating a single intervention under controlled conditions, which does not reflect the complexity and heterogeneity of real-world cancer care (1, 2). 

Cancer is a multifaceted disease involving numerous biological pathways and mechanisms, as described by the “hallmarks of cancer”—a conceptual framework that outlines the diverse capabilities cancer cells acquire during tumor development and progression. 

“The cure for cancer? It all started with a single case study.”

Why You’re Reading This Here—Not in Mainstream Media

Most mainstream doctors will dismiss fenbendazole as ineffective. But have they actually read the case reports presented in this article? Most likely, they have not. And if they have, they may dismiss these case reports as biased or of low-quality evidence—implying that more than 180 patient testimonials are simply false. Yet when faced with a stage 4 cancer diagnosis for themselves or a loved one, many may revisit this article for a second look.

You may have also found this article through a social media link rather than mainstream news outlets or major search engines. Why is that?

Unlike traditional platforms, social media allows the rapid sharing of niche or under-represented stories—giving content like this a chance to reach those who might otherwise miss it.

When diagnosed with cancer, most people rely on discussions with family members and doctors. However, they often encounter conflicting recommendations—some professionals support exploring fenbendazole, while others strongly oppose it.

Navigating Fact and Fiction

So, what’s fact and what’s fiction? The answer depends on science and research. However, science can be biased, manipulated, or selectively presented to fit a particular narrative. That’s why it’s crucial to do your own research in consultation with a trusted doctor. Many media references rely on outdated studies or cherry-picked data that align with a specific viewpoint.

Note: Do we have any conflicts of interest? Are we trying to sell you something? The information in this article is provided completely free of charge—there’s no need to purchase anything or make any payment to us.

Real Stories, Real Hope

Many people immediately dismiss the potential of fenbendazole when they learn it is “dog medicine.” That initial reaction is overcome when the success stories regarding fenbendazole and cancer are told including the lack of serious side effects.

The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights and clues that may be valuable to those searching for better options.

It's important to note that many of the cases below involve stage 4 cancers that have failed conventional treatments. Achieving a Complete Response (CR) or No Evidence of Disease (NED) is uncommon, especially after chemotherapy failure. Complete responses in stage 4 cancers are rare and represent exceptional outcomes given the advanced disease and limited treatment options at this stage.

If you or a loved one have a matching cancer subtype, it can be especially compelling to consider trying fenbendazole and/or ivermectin —particularly when dealing with aggressive cancers that have low survival rates, such as triple-negative breast cancer or stage 4 pancreatic cancer.

The Case for a Precautionary Approach

According to The Cochrane Review’s editor-in-chief, Karla Soares-Weiser (source):

“Lack of evidence of effectiveness is not evidence that the interventions are ineffective… Waiting for strong evidence is a recipe for paralysis. Public health officials must take measured gambles, based on circumstantial evidence from the reviewed studies and other sources. When protecting the public from harm, they must act even when evidence is uncertain (or not of the highest quality), particularly when the harms and costs of such action are likely limited.”

Even if the chance of fenbendazole helping is small, individuals have the right to explore it as an option.

Dr. John Campbell, a health educator with over 3 million YouTube followers, shared (video) a compelling perspective in his video on fenbendazole and ivermectin for cancer:

“People have the right to try. They could try these drugs... and we could track them over time. We could build national cohorts of tens of thousands of patients in no time… then hand it over to statisticians to analyze the data and uncover the mathematical truth. This could be done, and in my view, it should be done.” - Dr John Campbell

"When you've tried everything, sometimes it's the unexpected that brings the miracle." - One Day MD

A Final Word of Encouragement

If you have stage 4 cancer, don’t lose hope. Your story could be the next inspiring success.

“N=1 is the future.” – Michael Snyder, Stanford Medicine (source)

Instead of relying solely on large-scale studies, case reports focus on individuals—allowing people to directly assess how specific interventions affect their unique health profiles in the real world. As Snyder told The Epoch Times, “We are all different, and now we can collect a lot of data on a single person or a few individuals to make very specific recommendations.”

In the end, science evolves. Until then, the right to try belongs to you.

Important Disclaimer

It is important to acknowledge that the Fenbendazole protocol is not a universal cure for cancer. We do not advocate for or against any treatment—whether conventional (such as surgery, chemotherapy, radiation, immunotherapy), alternative, complementary, or adjunctive approaches. Our focus remains on effective and safe integrated and personalized strategies that may offer hope and improve outcomes for patients.

This article is not intended to be your definitive guide but rather a step in your journey toward the best possible health. It emphasizes that fenbendazole and other approaches may form part of a comprehensive, multi-modal cancer treatment strategy tailored to your individual needs. For cancer patients and caregivers, these case reports give you structure, safety checkpoints, and conversation tools you can use with your doctor. We encourage you to seek additional resources, ask questions, and explore all available options, including conventional treatments such as surgery, chemotherapy, radiation, targeted therapy, immunotherapy, and hormone therapy, as well as emerging modalities. Personalized treatment plans developed with your healthcare team offer the best chance for effective management and improved outcomes.

Best Ivermectin Dosage for Humans
Ivermectin Dosage for Humans with Cancer

Read more: Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types (2026)

fenbendazole dosage for cancer in humans
Fenbendazole Dosage for Humans with Cancer


Ivermectin and Fenbendazole for Cancer Case Series Compilation

The following success stories were gathered from various web and social media sources, providing anecdotal, crowd-sourced information.

The list of fenbendazole related cancer case reports below is organised alphabetically by cancer type.

Note on case counts: Totals shown in the TOC above reflect the complete number of cases across each cancer type's dedicated sub-article (where one exists). This main page presents selected representative cases inline; click "Read More" under each section to access the full case series.

Navigation tip: This is a lengthy article. To jump to a specific cancer type, use Command+F (Mac) or Control+F (Windows) to search the case reports or testimonials.

1. Breast Cancer Success Stories (123 Cases)

The compilation includes over 120 ivermectin and fenbendazole for breast cancer case reports. Full details are provided in this article: Fenbendazole, Ivermectin and Mebendazole for Breast Cancer Success Stories.

2. Brain Cancer Success Stories (125 cases)

The compilation includes 110 ivermectin, fenbendazole or/and mebendazole for brain cancer case reports. Full details are provided in this article: Ivermectin and Mebendazole for Brain Cancer Success Stories.




Ivermectin and mebendazole, both approved for human use, are now available in the U.S.

Researched and approved by Dr. Peter McCullough.
  • Prescribed by licensed medical professionals
  • Compounded and dispensed by a licensed US-based pharmacy
  • Approved for human use
  • Lab-tested for potency, with doctor consultation included and free U.S. shipping.
  • 99 of 106 verified reviewers gave the combo 5 stars.
Where to buy Ivermectin and Mebendazole Formula: Available on The Wellness Company's website. Here is the link: Ivermectin and Mebendazole.

3. Bladder Cancer Success Stories (27 cases)

Read More: Fenbendazole and Ivermectin in Kidney-Urinary Cancers: 2021 Stanford University Case Series and More (27 Case Reports) 

4. Cervical Cancer Success Stories (6 cases)


5. Colorectal Cancer Success Stories (80 cases)

Read More: Fenbendazole and Ivermectin for Colorectal Cancer (80 cases)

6. Esophageal and Stomach (Gastric) Cancers (11 cases)


7. Endometrial (Uterine) Cancer (11 cases)


8. Gastric (Stomach) Cancer: Fenbendazole and Ivermectin


9. Head and Neck Cancer Success Stories (16 cases)


10. Kidney Cancer Success Stories (27 cases)

Read More: Fenbendazole and Ivermectin in Kidney-Urinary Cancers: 2021 Stanford University Case Series and More (27 Case Reports) 

11. Liver and Bile Duct Cancer (Hepato-biliary System) Success Stories (9 Cases)

11.1 Liver Cancer Success Stories: Fenbendazole (4 cases)

Case No. 4: 73 year old Massachusetts man with 2 liver cancers and liver transplant candidate

In a May 2026 post on X, Dr. William Makis wrote:

73 year old Massachusetts man with 2 liver cancers and liver transplant candidate reports after 10 months of IVERMECTIN & MEBENDAZOLE: tumors shrinking & will get his Liver Transplant! Patient with 2 liver cancers and on list for LIVER TRANSPLANT does so well on Ivermectin and Mebendazole, that he's getting his LIVER TRANSPLANT now in a few weeks! 73 year old Massachusetts man with 2 liver cancers (Cholangioca and HCC) In April 2025 he started: Ivermectin 1mg/kg/day Mebendazole 1000mg/day Results after 10 months: HCC Shrinking (Segment 4A/8) Cholangiocarcinoma (Segment 4) no longer seen He will get his liver transplant this month! Remember all those incompetent doctors who said Ivermectin and Mebendazole hurts the liver? If you've ever heard your doctor say that, fire your doctor immediately, because if they were willing to lie to you about this, they will lie to you about anything. This is a game changer for Liver Cancer patients who are looking at improving their chances of getting a LIVER TRANSPLANT.


Case No. 3: 44 year old Australian Man with Hepatocellular Carcinoma (HCC)

Dr. William Makis shared on X (Twitter) in July 2025:

Ivermectin and Mebendazole Testimonial - 44 year old Australian Man with Hepatocellular Carcinoma (HCC) reports success after 3 months A success story all the way from Australia! I'm actually helping many cancer patients in Communist Australia, where it's much harder to get Ivermectin and Fenbendazole but where there's a will... 44 year old Australian Man with Hepatocellular Carcinoma (HCC) Late Feb 2025 we started:
  • Ivermectin 1mg/kg/day
  • Mebendazole 1000mg/day
  • Melatonin 300mg/day
Results after 3 months: Tumor markers decreased by 25% Liver lesion decreased from 37mm to 30mm = 46% tumor volume shrinkage CT: "Significant decreased volume and extent of enhancement of the hepatic lesions from prior" From patient: "Looks like I am going in the right direction. Thanks a lot for your help"

HCC is extremely difficult to treat and Oncologists have no answer for it.


Case No. 2: September, 2021

I was given less than two years to live in 2020 when I was diagnosed with stage 4 (metastatic) HCC (HepatoCellular Carcinoma) liver cancer. I received radiation directly onto the tumors and went for immunotherapy which did not bring any improvement to my state I was in. My wife and family did research and came across the fenbendazole protocol. I had nothing left to lose, so I decided to give it a try.

Case No. 1: September, 2021

In 2021 the doctor discovered a tumor growth at the end part of my colon. The test results declared a colon tumor with some small lesions on my liver back then. This was a lot to take in considering the thought of having to go through surgery and a colostomy. I have been a super active person for almost all of my life, taking my vitamins on a daily basis as I start my day – I never thought that something like this could ever happen to me.

After I made peace with what was happening inside my body, I gathered myself and started seeking for the best possible advice/guidance out there on any alternative approach other than putting my body through all this stress. I managed to start a protocol on: 1mg FECO, RSO oil which I used on the daily, and supplements at night along with some juicing which includes soursop & green tea, 20000mg Vit D, 5000mg Vit C & Vit K, 800mg grape seed extract, 2100mg ashwagandha, 1950mg curcumin with ginger & black pepper, sea cucumber extract, and 2000mg Fenbendazole on a daily basis (½ in the morning; ½ at before bed).

I never told my doctors about this and continued with treatment alongside the use of this protocol. A few months has passed since I started this journey and I received my results again later that year, showing no presence of any tumor. It completely vanished into thin air! After only four chemo treatments the doctor could not comprehend how the cancer just managed to disappear like that, and so quickly too – considering the time period for chemo to work to be proven to take much longer before it actually starts working.

See Bile Duct Cancer (Cholangiocarcinoma) below.

11.2. Bile Duct Cancer (Cholangiocarcinoma) (5 cases)

Case 5: 77 year old UK woman with Cholangiocarcinoma

Dr. William Makis posted on X.com in June 2026:

IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial - 77 year old UK woman with Cholangiocarcinoma reports after 8 months: tumors shrinking, doing better than others on chemo... STORY: 77 year old UK woman with Cholangiocarcinoma. In July 2025 she started: Ivermectin 1mg/kg/day Mebendazole 1000mg/day Chemo Results after 8 months: tumors shrinking: “cancer has shrunk” “mum’s overall health has improved, she is no longer on painkillers” “Mum started chemo…she has noticed she seems to have fewer side effects compared to other patients” Patients on Ivermectin & Mebendazole usually have significantly less side effects when taking chemo or radiation therapy, due to reduced inflammation and enhanced cancer cell killing. Ivermectin's anti-inflammatory effects are well documented in the published literature.


Case 4: 75 year old FLORIDA man with 14 cm Intrahepatic Cholangiocarcinoma

Dr. William Makis posted on X.com in January 2026:

IVERMECTIN and MEBENDAZOLE Testimonial - 75 year old FLORIDA man with Intrahepatic Cholangiocarcinoma reports after 3 months: 14cm tumor necrotic inside!
A positive "Florida man" story for a change! 75 year old Florida man with Cholangiocarcinoma On August 13, 2025 he started: Ivermectin 105mg/day Mebendazole 1000mg/day From the patient: "Dr.Makis, my Oncologist is very pleased with my response to chemo and immunotherapy treatments....she is amazed at how well I am tolerating the treatments and is not aware I am using your protocol of Ivermectin, Mebendazole, etc..." "I'm glad you got to help us here in Florida with your recent visit" PET Nov.24, 2025: "large infiltrative mass involving majority of the right hepatic lobe...on today's exam this does demonstrate central regions of photopenia compatible with necrotic change." Key POINTS: 1. Ivermectin and Mebendazole significantly reduce chemo side effects!! 2. TUMOR NECROSIS - I have seen this happen several times, so I am raising it as an important thing to keep an eye on. Large tumors, especially Cholangiocarcinomas, will first die in the center when responding to Ivermectin and Mebendazole (and usually chemo). During this time, the tumor size itself may not change, but inside the tumor, usually in the center, the tumor liquifies as it is dying. This is described as “necrosis”, or hypodense on CT, or “photopenia” on PET/CT (as there is no cancer metabolism going on in dead tumor tissue so it doesn’t light up on PET scan) The tumor size eventually starts to decrease but it takes several months for the body to remove a significant amount of dead cells from inside the tumor to make that obvious on CT.


Case 3: 85 year old Toronto, Ontario man with Cholangiocarcinoma (Klatskin Tumor)

Dr. William Makis shared on X.com in December 2025:

IVERMECTIN, FENBENDAZOLE, CBD Oil Testimonial - 85 year old Toronto, Ontario man with Cholangiocarcinoma (Klatskin Tumor) reports after 4 months - goes from progressing to Complete Remission!

Trigger Warning! This post may cause seizures in some because there is no chemo and no mainstream Oncology Treatment. You have been WARNED!!
STORY: 85 year old Toronto, Ontario man with Early Stage Cholangiocarcinoma, 2.8cm tumor involving common hepatic and common bile ducts. From June 21, 2025 to Oct.15, 2025 (4 months) he took:
  • Ivermectin 64mg/day, then 48mg/day
  • Fenbendazole 500mg/day
  • CBD Oil 100mg/day
Results after 4 months: Complete Remission!! KEY POINTS: No chemo, no radiation, no immunotherapy. Yes, he had radiation 5 months before starting the Ivermectin Protocol (in Jan.2025) but May 2025 CT showed his tumor was still growing after the radiation therapy!! The bile duct tumor grew to 2.8cm from 2.3cm after radiation therapy. An 85 year old man can take Ivermectin and Fenbendazole safely with no side effects. This really puts into perspective when I hear from 40 year olds who are afraid to take either, because their Oncologist told them it could be “dangerous”. These were mild doses of Ivermectin and Fenbendazole. Some tumors respond incredibly well to Ivermectin, Fenbendazole, Mebendazole, even at mild doses. Cholangiocarcinomas are in this category. This was truly the simplest possible solution and the patient is now in remission. I often present Stage 4 cases but remember, this is an early stage case, and shows you what is possible if you start Ivermectin and Fenbendazole at a much earlier stage.


Case 2: 48 year old TEXAS woman with Stage 4 Cholangiocarcinoma

Dr. William Makis shared on X.com in December 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 48 year old TEXAS woman with Stage 4 Cholangiocarcinoma. "She lasted in Palliative Care Unit twice as long as anyone expected"
Sometimes you get a beautiful story from Hospice... You will have to read the whole story but here is a highlight: "I did want you to know though...it was the only thing she took (secretly) while in the hospital for her last month." "She was in multi organ failure... but her kidney doctor kept saying, "I've never seen this before, but your kidneys seem to be improving in function. I have no idea why."  But we knew why. (I have another cousin with stage 4 breast cancer who is also using IVM & FBZ and her kidneys were weeks away from dialysis and now are normal function. All she takes is IVM & FBZ).  "Anyway... XXXXX lasted in the Palliative Care Unit at XXXX twice as long as anyone expected. She took IVM & FBZ consistently her last three weeks in hospital and that gave her a little more time with family and friends." "THANK YOU. Your research and constant perseverance makes a BIG difference... People are researching and pursuing alternative protocols for their health because of you. And they have HOPE!"


Case 1: 53 year old Stage 4 Cholangiocarcinoma Cancer patient with 15 cm tumor

Dr William Makis shared on X/Twitter (December 2024 update):

IVERMECTIN and FENBENDAZOLE Testimonial - 53 year old Stage 4 Cholangiocarcinoma Cancer patient with 15cm tumor declared "Cancer Free" after reaching out to me 14 months ago!! This is a very special story. 53 year old Canadian Cancer patient diagnosed with Stage 4 Cholangiocarcinoma, metastatic to liver in March 2023. Multiple lesions, largest 15cm. Patient had chemo and reached out to me in October 2023. "I was taken off the bag of immunotherapy because the tumour didn't shrink" "Second oncologist...was worse than the oncologist I have now...told me my supposed mortality chart and to watch for "the end" because I'd be lucky to make it to summer (2024)"

"I'm terrified...I'm losing hope" I replied on Nov.3, 2023: "Don't lose hope..
  • Ivermectin is 1mg/kg/ or 2mg/kg daily
  • Fenbendazole is typically 444mg daily
  • Melatonin is 100mg-300mg daily" (see note below)
Life went on...then I get an email in July 2024: "I'm still here thanks to you :)"

We went to work. Oncologists were pressuring to give her more and more chemo.  In November 2023, she had started Fenbendazole 444mg (Panacur) and Melatonin 100mg

In August 2024 we added 150mg of Ivermectin or 2.5m/kg/day, and CBD-THC Oil. You heard that right. Ivermectin 2.5mg/kg/day. And then... December 12, 2024: "Cancer Free".

Note: "Melatonin induces apoptosis in cholangiocarcinoma cell lines by activating the reactive oxygen species-mediated mitochondrial pathway" (source)






Related: 

12. Lung Cancer Success Stories (46 Cases)


13. Leukemia (Acute Myelogenous Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL) (10 Cases)


Case 9: 56 year old Illinois man with Chronic Myeloid Leukemia (CML)

Dr William Makis posted on X.com in January 2026:

IVERMECTIN and FENBENDAZOLE Testimonial - 56 year old Illinois man with Chronic Myeloid Leukemia (CML) shares his success story!

Sometimes Cancer patients send me their success stories full of enthusiasm and optimism STORY: 56 year old Illinois man with Chronic Myeloid Leukemia (CML) Started Ivermectin and Fenbendazole in July and saw his WBC count drop 78.6 to 7.99 within 2 months October 2025: "The very first thing the doctor said was: "someone told me you had leukemia but I can't find it" "Dr. seems very happy and a little surprised at how well he is doing!" Jan.2026: "I reached major molecular response below 0.1%...which is considered remission! This is usually achieved after 18 months...WBC 4.27"


Case 8: 56 year old North Carolina man with Chronic Lymphocytic Leukemia (CLL) (Part 2)

Dr William Makis updated on X/Twitter in January 2026:

IVERMECTIN and MEBENDAZOLE Testimonial - 56 year old North Carolina man with CLL Leukemia reports after 8 months - normalization of blood work, Oncologist changes follow-up from 3 to 6 months.
Leukemia success stories are amazing because mainstream Oncology claims NOTHING helps outside chemo. STORY: 56 year old North Carolina man with CLL Leukemia In May 2025 he started:
  • Ivermectin 1mg/kg/day
  • Mebendazole 1000mg/day
  • CBD Oil 100mg/day
Results over 8 months: WBC 13.3 to 12 to 10.7 to 10.0 Lymphocytes: 10.11 to 6.24 to 4.39 KEY POINTS: Leukemias are tricky cancers Some CLL cases respond amazingly and obviously to repurposed drugs, while others don’t seem to. There is still a lot of research work to be done in this area, hopefully in Florida! What an easy solution this case was! No chemo!



Case 8: 56 year old North Carolina man with Chronic Lymphocytic Leukemia (CLL) (Part 1)

Dr William Makis posted (X/Twitter) in October 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 56 year old North Carolina man with Stage 0 Chronic Lymphocytic Leukemia (CLL) normalizes blood counts after 4 months.
I'm always happy to see Leukemia success stories, because Leukemia is not easy! STORY: 56 year old North Carolina man with Chronic Lymphocytic Leukemia (CLL) Stage 0 He had NO COVID-19 Vaccines He had NO chemo He had NO conventional Oncology treatment On May 16, 2025 he started:
  • Ivermectin 1mg/kg/day
  • Fenbendazole 1000mg/day
Oncologist had him on "watch and wait", meaning you watch until your Leukemia gets worse. Results after 4 months: Lymphocytes 10.11 to 4.39 WBC 13.3 to 10.7 There is no mistaking the results. Once again for those who are slower than the rest: He had no CHEMO He had no Oncology Treatment of any kind. According to mainstream Oncology, this is impossible and this patient shouldn't exist. Yet he does and he's quite happy with the results.


Cases 6 - 7: Acute Myelogenous Leukemia (AML) patient and Chronic Lymphocytic Leukemia (CLL) patient

2 Case testimonials from Dr William Makis (X/Twitter) in January 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - Two blood Cancer Cases: Acute Myelogenous Leukemia (AML) patient becomes "cancer free" and Chronic Lymphocytic Leukemia (CLL) patient improves 1st time in 2 years! Case 1: AML Patient diagnosed in October 2024 Immediately started 72mg Ivermectin and 1000mg Fenbendazole 3 days on 4 days off Also did 2 rounds of chemo in November and December, and in December added oral chemo pill Venclexta Results after 2 months of Ivermectin & Fenbendazole: "His bone marrow biopsy from December 24th came back clear! His blood work is looking good." "We are so thankful for men like you that are willing to do the right thing in the face of great persecution" ====== Case 2: 63M CLL patient with a high WBC count in Sep.2022, on “watch and see” I didn’t go aggressive here, started: 70mg Ivermectin and 500mg Mebendazole: Results: WBC 16.1 (Oct.2) → 15.6 (Dec.6) —> 14.1 (Jan.15) Lymphocytes 13.0 (Oct.2) —> 12.5 (Dec.6) —> 11.3 (Jan.15) On Dec.11 I made a few minor adjustments: increased from 500mg to 1000mg/day Mebendazole and added 1000mg/day Lactoferrin. After 2 years of being abnormal, the WBC and Lymphocytes are trending towards normal range (almost there)! "It is definitely trending down since beginning the protocol" Right now, there is only one peer reviewed publication that has documented the use of Ivermectin in Human Cancer Patients. Can you guess what the Cancer is? Leukemia. And it's behind a paywall. 2020 de Castro: "Continuous high-dose Ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection"







Case 5: Adult T-cell Leukemia/Lymphoma (ATL)

A patient with ATL and HTLV-1 infection was successfully stabilized and discharged after a combination of ivermectin and chemotherapy. The authors note that ivermectin may have contributed to disease control, but no firm conclusions can be drawn​. (Lai Yuwen et al 2025)

Case series 4 (2025): Several patients with Blood cancer (Leukemia, Lymphoma) and parasitic infections

Several patients receiving hematopoietic stem cell transplants or undergoing treatment for leukemia were treated with ivermectin for Demodex or other parasitic infections. In these cases, skin symptoms resolved rapidly, and patients remained stable over the short-to-intermediate term, though direct anticancer effects were not confirmed​. (Lai Yuwen et al 2025)

Case 3: 80 yr-old female with Acute Myeloid Leukemia (AML)

A female patient diagnosed with crusted scabies showed improvement after treatment with 9 mg ivermectin (days 1, 2, 8, 9, and 15) and systemic 5% permethrin cream for seven days. Two weeks later, all the skin lesions in the patient were repaired. (Lai Yuwen et al 2025)

Case Series 2 (2020): Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia (AML).

In the case series by De Castro et al. (2020), a daily dose of 1 mg/kg was administered for six months. This regimen was found to be well tolerated, with no major side effects reported throughout the treatment period. Notably, the authors also observed clinical benefits associated with this dosing protocol.

Case 1: 6-year-old male with Acute Lymphoblastic Leukemia (ALL) and Demodex folliculorum infestation

A 6-year-old male with ALL remained well and in long-term remission after ivermectin treatment for Demodex folliculorum infestation. 200 μg/kg ivermectin and 5% permethrin cream were administered, and the treatment was repeated after seven days; the rash did not recur. No relapse or progression noted at follow-up​. (Int J Dermatol 2003) 

14. Lymphoma Success Stories (25 cases)


Case 18 (2026): 36 year old man in South France with Stage 4 Hodgkin Lymphoma

Dr William Makis posted on X.com in February 2026:

IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial - 36 year old man in South France with Stage 4 Hodgkin Lymphoma reports after 1 month Cancer Patients in South of France benefiting! STORY: 36 year old man in France with Stage 4 Hodgkin Lymphoma
In December 2025 he started (Makis Triple Therapy): 
  • Ivermectin 1.5mg/kg/day
  • Fenbendazole 1500mg/day
  • Mebendazole 1500mg/day
KEY POINT: “Your protocol has already helped since I did not get any side effects from last (chemo) treatment done January 5th”.


Case 17 (2026): 40 year old Canadian man with DLBCL Lymphoma (Diffuse Large B-Cell Lymphoma) 9cm and 4cm masses in the right supraspinatus muscle

Dr William Makis posted on X.com in January 2026:

IVERMECTIN and FENBENDAZOLE Testimonial - 40 year old Canadian man with DLBCL Lymphoma 9cm and 4cm masses in the right supraspinatus muscle reports after 8 months - Cancer Free! 

Lymphomas can be incredibly responsive!  STORY: 40 year old Canadian man with DLBCL Lymphoma 9cm and 4cm masses in the right supraspinatus muscle. In May 2025 he started:
  • Ivermectin 1mg/kg/day 
  • Fenbendazole 1500mg/day 
  • CBD Oil 100mg/day
Results after 3 cycles of Chemo (with Ivermectin Protocol): CANCER FREE "My Oncologist stated after the 3rd round the cancer had disappeared".
"6 rounds R-CHOP - complete metabolic response. Cancer has disappeared".
"No side effects during treatment". KEY POINT: Soursop shows up in a lot of my success stories, even when I didn’t suggest it. That’s one of the reasons I started including it in my protocols regularly.

Soursop. Graviola. Add it to your diet. Don't be without it.


Case 16 (2026): 60 year old Massachusetts man with Stage 4 DLBCL (Diffuse Large B-Cell Lymphoma) metastatic to bones

Dr William Makis posted on X.com in January 2026:

IVERMECTIN, FENBENDAZOLE and IP6 Testimonial - 60 year old Massachusetts man with Stage 4 DLBCL LYMPHOMA metastatic to bones achieves remission in less than 2 months!

We sometimes see incredible responses and in a short period of time!

60 year old Massachusetts man with Stage 4 DLBCL LYMPHOMA metastatic to bones. In October he started taking IP6 In November, he started:
  • Ivermectin 1mg/kg/day 
  • Fenbendazole 1776mg/day
By Dec.29, he was in “Complete Remission”. KEY POINTS: This is an incredible treatment response in such a short period of time - one month on the full protocol to complete remission, and some of the lymphoma tumors were quite large, the largest was 6cm!

We often see in preclinical studies that Ivermectin and Fenbendazole can dramatically improve the cancer cell killing efficacy of chemotherapy. This is a perfect example of that.


Case 15 (2025): 70 year old Oklahoma man with Stage 4 Follicular Lymphoma metastatic to bones

Dr William Makis posted on X/Twitter in December 2025:

IVERMECTIN, FENBENDAZOLE, CBD Oil Testimonial - 70 year old Oklahoma man with Stage 4 Follicular Lymphoma metastatic to bones reports after 6 months - Remission!

Stage 4 Cancer to remission, success story after success story.
STORY: 70 year old Oklahoma man with Stage 4 Follicular Lymphoma metastatic to bones In early April 2025 he started: Ivermectin: 1mg/kg/day Fenbendazole 1000mg/day CBD Oil 100mg/day Oncologist: 6 rounds of RCHOP starting late May Results: By July 22, 2025 his PET scan was clean!! The images shown are of his May 22, 2025 (extensive metastases) and July 22, 2025 (clean) PET scans. At this point he had been on IVM/FBZ 3-4 months. Remission was confirmed again on a Sep.30, 2025 PET Scan. KEY POINTS: I now have Lymphoma success stories with complete remissions (confirmed by PET scans) of the following combinations: Ivermectin + Fenbendazole + RCHOP Ivermectin + Mebendazole + RCHOP Which is better? Literature seems to lean towards Mebendazole but I don’t have a definitive answer. Both seem to work. That's wonderful news for cancer patients who sometimes have trouble getting one or the other (Fenbendazole or Mebendazole). From Stage 4 Cancer to remission is much more likely if you incorporate repurposed drugs.






Case 14 (2025): 65 year old Canadian Man with T-cell Anaplastic Lymphoma of the tonsils

IVERMECTIN and FENBENDAZOLE Testimonial - 65 year old Canadian Man with T-cell Anaplastic Lymphoma of the tonsils reports after 3 months.
On my way back home from El Salvador...what better time to post a testimonial? STORY: 65 year old Canadian Man with T-cell Anaplastic Lymphoma of the tonsils In early July 2025 he started: Ivermectin 1mg/kg/day Fenbendazole 1000mg/day Chemotherapy Results: After the end of his 3rd chemotherapy (the CT Report here), his lymphoma sites had resolved. Ivermectin and Fenbendazole are chemosensitizers that enhance cancer cell killing by chemotherapy and we see very dramatic responses in many Lymphoma cases.

Source: https://x.com/MakisMedicine/status/1989435275810890033 (November 2025)


Case 13 (2025): Wife of UK Architect with B-cell Non-Hodgkin Lymphoma

FENBENDAZOLE Testimonial - Wife of UK Architect shares an incredible B-cell Non-Hodgkin Lymphoma success story!
I've helped over 7000 cancer patients directly and countless more "indirectly". Here is one of those heartwarming success stories. "I was diagnosed with Lymphoma B-Cell Non-Hodgkin's high grade" "the day I had my first chemotherapy in April he (my husband) showed me your interview with Dr.Campbell talking about the success of Fenbendazole" "I had nothing to lose, so we ordered some online and four days later I started taking it" Now, there is no Ivermectin in this story, so this one is really interesting... "I started taking 222mg per day and soon increased the dose to 444mg after reading the comments below your podcast. "I had a PET scan in June, and my haematologist was speechless. She had never seen this before, after one chemotherapy session, I had no more Lymphoma" "my PET scan last week again showed I had no more Lymphoma"
"This time she asked if she could write up my case and said if she prescribed Fenbendazole she would be struck off"


Case 12 (2025): 46 year old Canadian man with Stage II Hodgkin Lymphoma

Ivermectin and Fenbendazole Testimonial - 46 yo Canadian man with Stage II Hodgkin Lymphoma (9x7x11cm mediastinal mass) goes into remission after 3 months with Ivermectin, Fenbendazole and Radiation! An incredible story of lymphoma - from a massive 11cm mediastinal tumor to "Cancer Free". 46 year old Canadian man with Stage II Hodgkin Lymphoma (9x7x11cm mediastinal mass) From Dec.2024 to March 2025, for 3 months, he took:
  • Ivermectin 1mg/kg/day (increasing to 2mg/kg/day)
  • Fenbendazole 1332mg/day
  • CBD Oil 100mg/day
  • Melatonin 300mg/day
Results: The anterior mediastinal mass shrunk from 11cm to 2.9cm with no FDG uptake (could just be residual scar at this point) The Oncologist informed the patient that he is now in remission!

Source: https://x.com/MakisMD/status/1937984358432051382 (June 2025)


Case 11 (2020): 83-year-old male with Diffuse Large B-Cell Lymphoma (DLBCL)

An 83-year-old male, presented with heartburn, trouble swallowing, and fatigue. An Esophagogastroduodenoscopy (EGD) revealed superficial duodenal ulcer which was biopsied and revealed DLBCL, GCB subtype. Fluorescence in Situ Hybridization (FISH) was negative for c-MYC, BCL2 and BCL6. A Positron Emission Tomography/Computed Tomography (PET/CT) scan revealed hyper-metabolic activity in the distal gastric antrum, proximal duodenum, peri-aortic lymph node, and pulmonary nodules. Patient was staged as stage Iva, and was offered chemotherapy, but he declined treatment due to side effect profile.

He started to take fenbendazole 1g daily based on self-research (used to take between 1-6 tabs daily based on his symptoms). After 6 months, he cut down fenbendazole to 1-3 tabs daily due to peripheral neuropathy. He presented to his primary care physician who obtained a repeated CT scan which revealed smaller mediastinal lymph nodes. After 2 months, he decided to follow with oncology, so he had repeated PET/CT scan which revealed improved lymphadenopathy from prior scans.

In the next 3 months, he continued to taper down fenbendazole and reached 3 pills weekly. A repeated PET/CT scan revealed interval improvement in his disease with no new lesion seen.

Source: Annals of Hematology & Oncology 2020


Case 10 (2025): 65-yr-old male with Early Lymphoma

Mike Ridgway of Tennessee treated his early lymphoma with two shoeboxes of medications from India. Within eleven months, his three PET scans went from ominous to better to normal.

A retired software programmer, Ridgway took long-established, off-patent drugs that are surely not on a typical oncologist’s radar: ivermectin, fenbendazole (a veterinary drug), and colchicine. They cost $400 for six months of treatment. Standard pharmaceuticals for early lymphoma, by contrast, cost an average $12,396 a year in the United States.

Ridgway, who is sixty-five years old, represents a small share of cancer patients who choose alternative care in part because they mistrust profit-driven oncology and dislike the chemo drawbacks. The drugs they take—under the supervision of a physician and sometimes with traditional therapies—are supported by considerable laboratory and animal studies and some human research.

For cases in which the outcomes are known, he prescribed his ivermectin-fenbendazole cocktail to sixteen patients, who almost all had been given one to four weeks to live. Thirteen survived from six to ten months before dying, he said. One near-death pancreatic patient, who had exhausted the gamut of chemotherapy, lasted more than a year.

“It’s difficult to reverse the (chemotherapy) damage,” DeMello said, who has six other cases in various treatment stages.

In two of his first sixteen cases, however, patients bypassed traditional care and went first to DeMello. Rohini Hughes, a fity-three-year-old advanced colon cancer patient, is alive though suffering, twenty months after her remaining time was measured in days. Mike Ridgway, whose cancer was caught early, was given a clean bill of health nearly a year after the disease emerged.

“I cannot overstate how blessed my wife and I feel,” Ridgway said.

Ridgway became friends with DeMello through Facebook, where they shared like-minded views of the flaws of official pandemic policies.

Ridgway’s first inkling that he was facing a serious health problem was in February 2024 after suffering abdominal pain and enlarged lymph nodes. “This PET scan will find cancer anywhere in your body,” the technician told a startled Ridgway.

Indeed, the scan showed “two nodes in the left upper abdominal mesentery that are markedly hypermetabolic, and lymphoma is a primary consideration.”

An oncologist ordered a biopsy, telling Ridgway unequivocally, “The tissue is the issue.”

He turned to DeMello, who “was very, very emphatic against it,” Ridgway said.

“I am convinced that there is no useful role of biopsy (and risk of spreading cancer) especially when a non-invasive test like PET scan can confirm the presence of malignancy,” DeMello explained. “Two huge lymphomas” on Ridgway’s scan were diagnostic for him.

“Unless he had a major infection, with symptoms of fever, high WBC counts, high neutrophil counts,” he said, “the only diagnosis for such huge tumors in the abdomen is malignancy’.”

After that, Ridgway opted to follow the advice of a doctor he respected half a world away.

“It’s nothing short of a miracle that the two of us were in communication when I received my diagnosis for cancer,” he told me.

Source: Ivermectin and Fenbendazole May Just Quell Cancer - Mary Beth Pfeiffer


Case 9: 49 year old Georgia man with Stage 4 Diffuse Large B-Cell Lymphoma in mesentery

Dr William Makis shared on X/Twitter in May 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 49 year old Georgia man with Stage 4 Diffuse Large B-Cell Lymphoma in mesentery has almost complete response after 3 months and NO CHEMO! A lymphoma case. Almost complete response. The most shocking part: NO CHEMO! STORY: 49 year old Georgia man presented to ER in Oct.2024 with a large abdominal mass, pain and ascites. He was diagnosed with Stage 4 Diffuse Large B-Cell Lymphoma He had very bad side effects with 1st cycle of R-CHOP chemo and did not want to repeat any more chemo treatments. I don't know how they found me, but in early January 2025 we started: Ivermectin 1mg/kg/day Fenbendazole 1332mg/day RESULTS after 3 months: CT showed: "Significant treatment response. Mass-like conglomerate in the left abdomen on previous exam demonstrating significant improvement. Minimal residual mesenteric nodularity measuring 3x2cm" My Take…. Ivermectin and Fenbendazole are often dismissed as not having had any effect on the cancer when the patient also takes chemo. “Chemo did all the work”. But when there is no chemo, and the cancer shrinks or disappears, the critics are silent. There was no chemo in this case and the patient is almost cancer free after 3 months of Ivermectin and Fenbendazole only. Horrible side effects with chemo. No side effects with Ivermectin and Fenbendazole. We're going for "Cancer Free" on the next scan. I have had several Lymphoma success stories like this already. In this case, the patient was more than willing to do chemo but became so sick with the 1st cycle (losing 20+ pounds), that he couldn't do another cycle.


Case 8: 60 year old Oregon woman with Mantle Cell Lymphoma

Dr William Makis shared on X/Twitter in May 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 60 year old Oregon woman with Mantle Cell Lymphoma has up to 96% tumor shrinkage. STORY: 60 year old Oregon Woman was diagnosed with Mantle Cell Lymphoma and bowel involvement. As of December 2024 she was progressing on imaging scans. We started in December 2024:
  • Ivermectin 1mg/kg/day
  • Fenbendazole 888mg/day going to 1332mg/day
RESULTS after 3.5 months (CT results): Neck node: 9mm to 3mm (96.3% shrinkage) Mediastinum precarinal node: 7mm to 3mm (92.1% shrinkage) Right axilla node: 8mm to 4mm (87.5% shrinkage) Abdominal Node: 18mm to 7mm (94% shrinkage) How impressive is that? 88% to 96% tumor shrinkage From the patient: “Beyond the shrinkage, side effects almost non-existent.” “I’ve been feeling energetic and strong enough to do many hours of yard work, gardening, hauling debris and shoveling soil” “Feeling phenomenal” This doesn’t get talked about nearly enough. Ivermectin and Fenbendazole often REDUCE chemo side effects. This makes a huge difference to the overall Cancer treatment experience.


Case 7: 83 year old Florida man was diagnosed with extensive Stage 3 Follicular Lymphoma (a slow-growing type of non-Hodgkin lymphoma)

Dr William Makis shared on X/Twitter in April 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 83 year old FLORIDA Man with Stage 3 Follicular Lymphoma has a dramatic response (almost 100% resolution), Oncologist refuses to believe it! This is an incredible story for several reasons, but you'll have to read to the end, to find out  STORY:
83 year old Florida man was diagnosed with extensive Stage 3 Follicular Lymphoma Oncologist put him on “watch and wait” Patient came to me in early September 2024. We started the Makis Ivermectin Cancer Clinic Protocol in early October 2024:
  • Ivermectin 1mg/kg/day 
  • Fenbendazole 444mg/day 
  • Melatonin 120mg/day
RESULTS after 6 months, on PET/CT (April 2025): "Dramatic improvement in the lymphadenopathy previously seen in the axillary regions bilaterally. Previously the largest right axillary lymph node at approximately 3.4 x 1.9 cm, currently 1.0 x 0.7 cm. Previous maximum SUV of 9.5, currently 1.3" "Dramatic improvement in the retroperitoneal adenopathy" "IMPRESSION: Dramatic improvement of the lymphadenopathy from the neck all the way through the groin. No new or enlarging lymph nodes seen. Only mild activity seen within the right axillary lymph node. Other lymph nodes are not able to be discerned above background significantly improved from the exam September 2024." My Take: I have never seen a Radiology report use the word “Dramatic” three times in the same report. And I have seen 10,000s of PET/CT Reports. Radiologists don’t get emotional with their language.

No chemo. No radiation. Almost all the cancer is gone. But that’s not the best part of the story. Best part is the reaction of the Oncologist: “We discussed findings on PET…which did show improvement in his lymphadenopathy” “We had extensive discussion about PET imaging”

“Discussed waxing and waning nature of lymphadenopathy” TRANSLATION: Waxing and waning = “Cancer comes and goes.” In other words, the results are random. Yes, 99% of the cancer is gone but it was all coincidence. He then refused to do a follow-up PET scan in 6 months! Heaven forbid the excellent results would confuse him even more!

CONCLUSION: This is an incredible story because:

1. No chemo, no radiation, only "watch and wait" from Oncologist

2. 6 months of low dose Ivermectin & Fenbendazole
3. 99% of cancer gone (one mildly active little lymph node remained)

4. Oncologist says cancer comes and goes and attributes the results to coincidence. Chance.

I can assure you that when you have "extensive adenopathy from neck through groin" that is Stage 3 Lymphoma (with SUVmax up to 12.0 on PET/CT), it doesn't just disappear if you close your eyes and wait. 

This Florida Oncologist was so uncomfortable with the excellent results, he won't do a follow-up PET/CT scan. He'd rather close his eyes and pretend. Stay in the dark - it's the world he knows. But guess what, repurposed drugs like Ivermectin and Fenbendazole are revolutionizing Cancer Care and more and more Oncologists are going to get "uncomfortable" with results they don't comprehend...


Case 6: 94 year old male with Large T-Cell Lymphoma

February 2025 case study from Dr William Makis (X/Twitter):

IVERMECTIN Testimonial - 94 year old man with Large T-Cell Lymphoma and a mass on his foot refused radiation (before and after photos included!) 

"My father is 94 years old and was diagnosed with large T cell lymphoma. He had a golf ball sized tumor on the top of his foot at the bend of his foot. All the doctors he saw said it wouldn't go away without radiation." 

"At his age he chose not to do that. I talked him into trying Ivermectin. I started him on the 1mg/per kilogram as you suggested but my siblings fought me and said that was too much for him to take." 

"He has been taking 12mg for the last five months and his tumor is now smaller than a pea and it hasn't been breaking open and bleeding like it had been." 

"We are thrilled with the progress even the low dose of ivermectin has achieved." "Thanks for everything you are doing to help people all around the world"

I love my patients!!! 
No chemo. No immunotherapy. No radiation. 
Just. Ivermectin. 12mg.







Case 5: Young European Female with Large B-cell Lymphoma

November 2024 case study from Dr William Makis (X/Twitter):

IVERMECTIN and MEBENDAZOLE Testimonial - Young European woman with Large B-Cell Lymphoma cleared of cancer in 2 months! A young woman with Large B-Cell Lymphoma started a regimen of Ivermectin and Mebendazole in late May 2024.
  • Ivermectin 1mg/kg/day
  • Mebendazole 200mg/day
  • followed by R-CHOP x 2 cycles
Comparison between PET scans done in September and again in late November 2024 RESULT: Complete resolution of Large B-Cell Lymphoma on PET scans 2 months apart! European Oncologist’s advice was to NOT take Ivermectin or Mebendazole during chemo (they're no better than the mRNA poisoned, cognitively impaired Oncologists here). My advice was: “Please continue Ivermectin and Mebendazole during chemo”.



Case 4:  Female with Hodgkin's Lymphoma (December 2024)

Case testimonial from PerilousPeg (X/Twitter):

"Dr Makis, my daughter just beat Hodgkin’s lymphoma with these drugs, supplements and a few other lifestyle changes. No chemo. No radiation. I have been telling people who are commenting on her video on TikTok with questions qbout ivermectin and fenbendazole to follow you."


Case 3: 70s year old male with Diffuse Large B-Cell Lymphoma (December 2024)

Case testimonial from Dr William Makis (X/Twitter):

IVERMECTIN and FENBENDAZOLE Testimonial - 70s year old patient with Diffuse Large B-Cell Lymphoma - dramatic impact in first two weeks!! 70s year old USA patient recently diagnosed with LYMPHOMA. We started a high dose Ivermectin and Fenbendazole Protocol "We visited my husband's oncologist today and my Husband's blood results were the best we've seen them since the beginning of all this." "He has large B cell lymphoma"
 


Case 2: April, 2021

In 2020 my cancer returned, low grade lymphoma in the neck and chest. I refused to go on another course of chemotherapy and followed the Fenbendazole protocol instead. I decided not to inform the doctors on the protocol I will be using as they would argue that it is a crazy belief with no proof of success.

It is almost a year later today that I received my second biopsy and PET scan results coming back completely clear from any disease, meaning there were no signs of lymphoma found from the neck lymph node that was removed.

Case 1: December, 2021

My twin sister was diagnosed with stage 2 non-Hodgkin’s B-cell double hit lymphoma a few years ago, which is known to be a very aggressive cancer out there. She won the battle, but not so long ago found out that the lymphoma has returned.

As a family we had to weigh the options and see what the next best approach is to this fight against cancer and so her journey started on Fenben. Here is a list of the protocol and other supplements she used and still use today:
  • Fenbendazole (222mg for the first few months and the increased the doses to 444mg/double)
  • CBD
  • Curcumin
  • Vitamin E
  • Additional supplements (recommended by doctors in Mexico)
After she finished her second round of chemotherapy – the PET scan confirmed that she was cancer free, again, after being on the fenbendazole protocol along with the treatment she has been getting since. She still consumes fenbendazole as a preventative measure to ensure the cancer does not return ever again!


Related: Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (Annals of Oncology 2025)

15. Melanoma

Please refer to Skin Cancer (chapter 25)

16. Multiple Myeloma (8 cases)

Case 8 - 2026: 31 year old Arizona Man with Plasmacytoma (Multiple Myeloma) reports after 8 months

Dr William Makis posted on X (July 2026):

IVERMECTIN, MEBENDAZOLE, CBD, DMSO Testimonial - 31 year old Arizona Man with Plasmacytoma (Multiple Myeloma) reports after 8 months: Cancer Free! STORY: 31 year old Arizona Man with Plasmacytoma in T8 (Multiple Myeloma) In October 2025 he started: Ivermectin 1mg/kg/day Mebendazole 1500mg/day CBD 100mg/day DMSO 1/2 tsp in glass of water twice/day Oncologist: Radiation Results after 8 months: "Today my son's MM specialist confirmed he is in remission - cancer free" "I want to know what needs to happen now at this stage. I want to help him stay cancer free" Multiple Myeloma is a blood cancer that can invade the bones and is very difficult to deal with, for mainstream Oncology.



Case 7 - 2026: 45 year old Cameroon woman in NIGERIA with Multiple Myeloma & bone lesions

Dr William Makis posted on X (April 2026):

IVERMECTIN and MEBENDAZOLE Testimonial - 45 year old Cameroon woman in NIGERIA with Multiple Myeloma & bone lesions reports after 12 months: complete resolution on PET of bone lesions & normal blood! STORY: 44 year old Cameroon woman in NIGERIA with Multiple Myeloma & lytic bone lesions. In Feb.2025 she started Ivermectin and Mebendazole. Oncologist: Velcade, Revlimid, Cyclophosphamide, Dexamethasone. Results after 12 months:
  • Complete metabolic resolution of bone lesions
  • Normalization of blood work!


Case 6 - 2025: 52 year old Massachusetts woman with severe Multiple Myeloma and 8cm Plasmacytoma

Dr William Makis shared on X (December 2025):

IVERMECTIN, MEBENDAZOLE, CBD Oil Testimonial - 52 year old Massachusetts woman with severe Multiple Myeloma and 8cm Plasmacytoma reports after 12 months - she is in Remission!

The good thing about leading the cutting edge of Cancer Care, is while Oncologists remain years behind, we are now getting LONG TERM results STORY: 52 year old Massachusetts woman with severe Multiple Myeloma and 8cm Plasmacytoma of shoulder/ribs In December 2024 she started: Ivermectin 1.5mg/kg/day Mebendazole 1000mg/day CBD Oil 100mg/day + conventional treatment Her bloodwork was REALLY BAD back in December 2024. Kappa FLC 757.3 (normal 3.3-19.4) Free Kappa/Lambda ratio 122.15 (normal 0.26 - 1.65) IgG 3330 mg/dl (normal 700-1600 mg/dl) It doesn't get much worse than this. One year later... All her bloodwork normalized and her 8cm plasmacytoma shoulder tumor is inactive on PET.


Case 5 - 2025: 62 year old Ontario man with Multiple Myeloma

Dr William Makis shared on X (November 2025):

IVERMECTIN and FENBENDAZOLE Testimonial - 62 year old Ontario man with Multiple Myeloma reports after 3 months - remission!
Multiple Myeloma is a tricky blood cancer, but I've now had several success stories STORY 62 year old Ontario man with Multiple Myeloma For 3 months he took:
  • Ivermectin 1.0mg/kg/day 
  • Fenbendazole 1000mg/day
  • D + VRD Induction (4 drug combination, standard initial treatment)
"3 months after beginning D + VRD Induction, including your recommended MM Protocol, his M-Protein was unmeasurable" "I do not believe we would be at this stage without your assistance". But there is a complication in this story: " XXX's cancer care team is pushing hard for re-vaccination post (stem cell) transplant" This is where this cancer patient will have to make some very difficult decisions. Re-vaccination is extremely dangerous. I'll leave it at that.


Case 4 - 2025: 67 year old New Jersey man with Multiple Myeloma and extensive bone lesions

Dr William Makis shared on X (October 2025):

IVERMECTIN and FENBENDAZOLE Testimonial - 67 year old New Jersey man with Multiple Myeloma and extensive bone lesions achieves remission after 6 months! Incredible story of remission! "Thank you, thank you, thank you from the bottom of my heart for saving my life." "Just six months ago I was diagnosed with Multiple Myeloma with 90 percent of my bones being invaded by this horrible disease" "On thursday after getting a bone marrow biopsy that was done two weeks ago I was congratulated by my Dr. that I am in remission. No evidence of any Myeloma in the bones". "I am currently taking 120mg Ivermectin and 440x3 of Fenbendazole"


Case 3: 49 year old Canadian woman with Multiple Myeloma

Dr William Makis shared on X (September 2025):

IVERMECTIN and FENBENDAZOLE and DMSO Testimonial - 49 year old Canadian woman with Multiple Myeloma has incredible results after 3 months An incredible success story with a very difficult cancer!! We have had some struggles with Multiple Myeloma, a blood cancer that can be incredibly difficult to deal with. But some patients have responded miraculously.
  • Ivermectin
  • Fenbendazole
  • DMSO


Case 2: 60 year old American woman with Multiple Myeloma

Dr William Makis shared on X (May 2025):

IVERMECTIN and MEBENDAZOLE Testimonial - 60 year old American woman with Multiple Myeloma sees improvement in blood work after 5 months! Multiple Myeloma is a very challenging blood cancer. 60 year old American woman was diagnosed with Multiple Myeloma in October 2024 She came to my Ivermectin Cancer Clinic in mid Nov 2024 and we started:
  • Ivermectin 1mg/kg/day
  • Mebendazole 1500mg/day
  • CBD Oil 50mg/day
Five months on Ivermectin/Mebendazole Protocol and we see a trend towards normalization of many blood values such as: Free K/L Light Chain Ratio (most important) Free Lambda Light Chain Gamma protein fraction Total Protein Multiple Myeloma has been one of the more challenging cancers for me to work with. Some patients respond to repurposed drug combination of Ivermectin and Mebendazole and some don't seem to respond at all. The blood cancers in general are really unpredictable but Oncologists are also extremely limited in the treatment options they offer these patients. So the risk/reward ratio here is still heavily skewed towards potential response and benefit with minimal to no side effects.


Case 1: January 2022* with January 2025 update

*Published as a January 2022 case testimonial on Heal Navigator but has been deleted.

17. Myelodysplastic Syndrome

Dr William Makis shared on X/Twitter (January 2025):

IVERMECTIN and FENBENDAZOLE Testimonial - 74 year old former Olympic athlete with Myelodysplastic Syndrome (MDS) post Moderna COVID-19 mRNA Vaccines - first improvement in blood counts in 2 years! Another short but inspiring story! 74 year old former Olympian had two Moderna COVID-19 mRNA Vaccines and recently developed MDS (Myelodysplastic Syndrome). From his wife: "I'm grateful I found you...he is on the Ivermectin and Fenbendazole regime I found on your site" After 1 month: "My husband had his blood tests last week and met with Oncologist today. For the first time in 2 years his blood counts are up and I can only attribute that to your Protocol of Ivermectin and Fenbendazole which he has been following for just a month" And now my favorite part  "You are a miracle worker and I think after the Rogan/Gibson podcast you will be very famous in the USA" Ok that was too sweet of her! The doses used for 1 month:
  • 24mg Ivermectin (daily)
  • 222mg Fenbendazole
These are relatively small doses but still effective! I've had many requests to help patients with Myelodysplastic Syndrome (MDS) and the research is very limited but guess what... several MDS patients and I are now working on it! Many blood disorders respond to Ivermectin and Fenbendazole and this is a hot area of research for those of us staying one step ahead of mainstream oncologists and hematologists!

18. Oral Cancer

Refer to Head and Neck Cancer: Fenbendazole and Ivermectin for Head and Neck Cancer (18 cases)

19. Ovarian Cancer Success Stories (18 Cases)

This compilation features several case reports involving the use of ivermectin and fenbendazole or mebendazole (benzimidazole) for ovarian cancer and related structure such as fallopian tube cancer.


20. Pancreatic Cancer Success Stories (48 cases)

21. Prostate Cancer Success Stories (130 Case Reports)

Read More: Fenbendazole and Ivermectin for Prostate Cancer Success Stories

22. Sarcoma* (8 cases)

*Sarcoma refers to a broad group of cancers that start in the bones and soft tissues. Soft tissues connect, support and surround other body structures. Soft tissues include muscle, fat, blood vessels, nerves, tendons and the lining of the joints. Cancer that starts in the soft tissue is called soft tissue sarcoma.

Case 8 - 2026: 65 year old Man in IRELAND with Spindle Cell Sarcoma of the Back reports after 9 months

In an August 2026 post on X, Dr William Makis wrote: (X.com)

IVERMECTIN and MEBENDAZOLE Testimonial - 65 year old Man in IRELAND with Spindle Cell Sarcoma of the Back reports after 9 months: Cancer Free! Ivermectin cancer revolution continues in Ireland! STORY: 65 year old Man in IRELAND with Spindle Cell Sarcoma of the Back near Scapula In August 2025 he started: Ivermectin 72mg/day Mebendazole 1000mg/day Had Surgery in October 2025 Got Ivermectin in South Africa and Mebendazole (Vermox) in Ireland Results after 9 months: Cancer Free! One of the goals of using repurposed drugs is to prevent recurrence in extremely aggressive cancers like sarcomas which have a habit of recurring with conventional Oncology treatments.


Case 5 - 2026: 12 year old California boy with Stage 4 Sarcoma (Radiation Induced)

Dr William Makis posted a follow-up update on X.com in July 2026:

12 year old California boy with Radiation Induced SARCOMA reports after 7 months of IVERMECTIN, MEBENDAZOLE and CBD Oil: Cancer Free! In his case, mainstream Oncology admitted they CAUSED his cancer! STORY: 12 year old California boy with Radiation Induced SARCOMA (Epithelioid and Spindle Cell) As a 1 year old he was treated with 54 weeks of chemo and 24 sessions of proton Radiation for an infratemporal Rhabdomyosarcoma. Considered cancer free until September 2025 when he presented with a headache and a new tumor at the site of previous Radiation. Had craniotomy in Sep.2025 and 85% of NEW Radiation induced tumor removed but suffered a stroke Then, in November 2025 he started:
  • Ivermectin 1mg/kg/day
  • Mebendazole 1500mg/day
  • CBD Oil 100mg/day
  • Proton Radiation Therapy, no chemo
Results after 7 months: Cancer Free! "...is 12 years old. Last scans in March showed no evidence of disease" This is one of those rare cases that mainstream Oncology admits they caused the Cancer. This boy has done extremely well after adding Ivermectin, Mebendazole and CBD Oil to his mainstream Oncology regimen. This time he had no chemo.

Dr William Makis posted on X.com in May 2026:

PEDIATRIC IVERMECTIN and MEBENDAZOLE Testimonial - 12 year old California boy with Stage 4 Sarcoma (Radiation Induced) Reports after 3 months: CANCER FREE!
STORY: 12 year old California boy with Stage 4 Sarcoma (Radiation Induced), metastatic to brain, neck lymph nodes and chest lymph nodes. In November 2025 he started:
  • Ivermectin 1mg/kg/day
  • Mebendazole 1500mg/day
  • Oncologist: He had head and neck radiation.
Results after 3 months:
CANCER FREE !! "Improving...last PET and MRI shows no progression, no evidence of disease. Shrinkage and resolution of lymph nodes..." "He is feeling much better" "According to the last PET the cancer has been resolved" How INCREDIBLE is this? Very few people know that Ivermectin and Mebendazole are FDA approved for safe use in children. They are also on the WHO list of "Most essential human medicines" There is also a Pediatric Clinical Trial with Mebendazole in child brain cancers.


Case 7 - 2026: 55 year old UK man with Stage 4 Turbo Sarcoma

In a June 2026 post on X, Dr William Makis wrote: (X.com)

IVERMECTIN and MEBENDAZOLE Testimonial - 55 year old UK man with Stage 4 Turbo Sarcoma reports after 6 months: improving! Ivermectin revolution is sweeping the UK despite their insane government sabotaging Ivermectin access! STORY: 55 year old UK man with Stage 4 Turbo Sarcoma (had 4 COVID-19 Vaccines ) Has been progressing since lung metastases were first identified in June 2022, still progressing as of August 2025. Since August 2025 started taking: Ivermectin 1.5mg/kg/day. Mebendazole 1500mg/day. Results after 6 months: “scans show condition stable, no new metastasis, recently SBRT treated area showing improvement” Sarcomas are very difficult to deal with and this is one area where mainstream Oncology has very little to offer.


Case 6 - 2026: 15 year old California girl with Synovial Sarcoma of Left Clavicle

Dr William Makis posted on X.com in June 2026:

IVERMECTIN and MEBENDAZOLE Testimonial - 15 year old California girl with Synovial Sarcoma of Left Clavicle reports after 3 months - tumor almost completely dead! STORY: 15 year old California girl with Synovial Sarcoma of Left Clavicle. In February 2026 she started: Ivermectin 1mg/kg/day Mebendazole 1500mg/day Chemo Radiation Results after 3 months: “shrinkage was only 15% but tumor was mostly necrotic and only the outer rim of the tumor from PET scan light up dimly” The tumor was essentially dead. Did you know that the first paper published on Ivermectin use in Human cancer was in three children with leukemia? A 2020 paper by a Brazilian research team of de Castro et al.


Case 4 - 2025: 61 year old Texas woman with 2 cancers: Sarcoma of arm metastatic to adrenal, and Neuroendocrine Cancer of the Lung

Case shared by Dr William Makis in August 2025 (X/Twitter):

IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial - 61 year old Texas woman with 2 cancers: Sarcoma of arm metastatic to adrenal, and Neuroendocrine Cancer of the Lung reports after 3 months Both are difficult cancers that Oncologists have almost zero success with! STORY: 61 year old Texas woman with 2 cancers: Sarcoma of arm metastatic to adrenal, and Neuroendocrine Cancer of the Lung, came to me for help. Patient took Ivermectin, Fenbendazole and Mebendazole for 4+ months starting March 10, 2025. Oncologist prescribed Keytruda. The synergy is well documented in the literature. Both Cancers responded extremely well: The sarcoma metastatic to adrenal (shrunk 3.4cm to 2.6cm) The Neuroendocrine lung Cancer (lung nodules shrunk 2.0cm to 1.2cm and 1.2cm to 0.7cm All other metastases shrunk as well. This has never been described.


Case 3: Stage 4 Leiomyosarcoma

@BattlingSarcoma shared on X (May 2025):

"@MakisMD I am trying your protocol on Sarcoma (Leiomyosarcoma) - rapid growth, a few inches a month, stage 4. Mebendazole + Ivermectin - no radio, no chemo no immuno, after a month I noticed it stopped growing and I no longer need blood transfusions. I will keep you updated."

Source: https://x.com/BattlingSarcoma/status/1905231385889030146

Useful related discussions under the comment section on X:

"My 14 year old is stage 4 osteosarcoma also. That's great news" (https://x.com/0x_abbie/status)

"Most likely he has Li-Fraumeni TP53 mutation just like me. Sarcomas affect young people. Many people suffered from Sarcoma in my family, chemo/radio did not work on anyone, made things worse." https://x.com/BattlingSarcoma/status/1912133810889671128

"After radio and resection of large retroparitoneal Liposarcoma in 2013, and another resection of recurrent pelvic tumor 2020, still growing. Last scan in 2/2025. measures 6.9 x 8.5 x 15 cm. began IVM, fenben, and niclosamide with alinea and tinidazole. Suggested by Dr Thomas Lodi"
"Also milk thistle and ALA for liver support, Vitamins ABCD and K2 mk7, Quercitin, turmeric, zinc and berberine, beta glucan and Nattokinase. Mostly vegan and juicing. Throwing everything at it."

"My wife has intimal sarcoma of the left atrium in the heat, Mets to bone, lung, scapula and subcutaneous, she had a surgery end Jan by March it had already grown to 4 cm and metastasized, doing chemo and maki’s protocol plus a bunch of supplements Also doing ddw water."

"My mom's BFF has that same cancer. I wouldn't be surprised if you know her only bc there are so few of you w that diag. She's survived 15yrs. She tried that protocol but it didn't take. I'm glad it's work for you! Her go-to for tumor maint/shrinkage is Honokiol and MCP."
"NIH studies on Honokiol shows that it works on the P34 pathway."
https://x.com/Anfoooey/status/1905403782453772592


Case 2: 70 year old woman with Stage 4 Spindle Cell Sarcoma

Dr William Makis updated on X/Twitter (Mar 2025):

IVERMECTIN and FENBENDAZOLE Testimonial - 70 year old woman Stage 4 Spindle Cell Sarcoma with lung metastases has tumor shrinkage! You don't hear many success stories from mainstream Oncology with Sarcoma! There's a good reason for that - chemo almost never works in these cancers. Here is yet another Ivermectin success story: 70 year old woman with Spindle Cell Sarcoma who lost her right leg. Now Stage 4 with lung metastases. She took the Joe Tippens Protocol of Fenbendazole 222mg/day and 12mg Ivermectin/day during chemo and her largest lung metastasis shrunk by 60%. “Had scan after chemo in Aug and had very good unexpected results - shrinkage of tumor by over 60% and disappearance of multiple other lesions.” She then gave me an update a few months later: “Have been off chemo for nearly 4 months, still taking Fenben, etc…and had a scan 3 weeks ago (Dec.2024)…my tumor had actually shrunk again! From 27x18mm to 22.7x12.3mm” Tumor shrunk again from 27x18mm to 22.7x12.3mm (another 60%). This story shows two important things: 1. Combination of chemo plus low dose Fenbendazole and low dose Ivermectin was sufficient to get 60% tumor shrinkage of lung metastases (and resolution of several lesions). Again, the combination of chemo + Ivermectin + Fenbendazole is very powerful, even in a difficult to treat cancer like SARCOMA. These are much lower doses than what I usually use and yet they were still effective. 2. She continued to take Fenben 222mg and Ivermectin 12mg while off chemo and had further tumor shrinkage of another 60%!

Dr William Makis shared on X/Twitter (November 2024):

IVERMECTIN & FENBENDAZOLE Testimonial - 70 year old woman with Stage 4 Spindle Cell Sarcoma gets 60% tumor shrinkage & multiple metastases disappear with low dose protocol 70 year old woman with Stage 4 Spindle Cell Sarcoma originally in the right leg, with lung metastases.
She took the following: 

Palliative chemo (was not expected to help and it's all the doctors had left to offer) 

222 mg Fenbendazole 3 days on / 4 days off (Joe Tippens Protocol) 
12 mg Ivermectin 3 days on / 4 days off 

Unexpected Results: tumor shrinkage by 60% & disappearance of multiple lesions (!!)

My Take… Spindle Cell Sarcoma is a cancer that’s notoriously difficult to treat. The response rate of chemo is on the order of 20% (which means 80% of patients don’t see ANY improvement). The ones who respond see minimal results. To get tumor shrinkage by 60% and disappearance of multiple lesions is stunning. The chemo was palliative and was not expected to help in this case.
 
So yes, it wasn't the chemo. Sorry. And these were VERY LOW doses of Ivermectin & Fenbendazole !! I tend to suggest higher doses as cancer killing with Ivermectin & Fenbendazole is dose dependent.




Case 1: September, 2023

Condition: Alveolar Rhabdomyosarcoma (Bone and Muscle cancer)

When my 13 year old son was diagnosed, I basically became a cancer researcher!
I discovered a few new very promising treatments that are close to being ready for pediatric use, and I also came across Joe Tippen’s story. I joined a couple of large, international Facebook groups related to the Protocol, which are by far the most positive of all of the cancer-related groups I’m in, and have the most success stories. I connected with a mom in the group whose 2 year old has the same type of cancer as my son, which had spread to his lymph nodes during frontline chemotherapy treatment. She started him on Fenben and his next 2 scans so far have been clear!
I would do anything to help my son beat the odds, and I came to the conclusion that it would be far more dangerous NOT to give him repurposed meds than to give them.
My husband supported my decision, but wanted some medical oversight, which we have received from Heal Navigator.
We noticed an improvement in our son’s energy level and general health after just 2 days of giving him the Fenben! He had zero side effects, besides feeling a lot better.
I hope and pray that is a sign that it’s doing what we need it to! If you’re hesitating about getting started, I would encourage you to go for it!

Protocol components used: Fenbendazole , Curcumin, Milk thistle, Ivermectin, Vitamin D3, Claritin, Melatonin, Propranolol, Niclosamide, Mushroom blend, Omega 3, Papaya Leaf Extract as needed to raise blood counts.

Conventional treatments: Radiation, Chemotherapy.

23. Skin Cancer and Melanoma (13 cases)

Case 13 - 2025: 81 year old woman living in Shanghai, China with Stage 4 Melanoma

Dr William Makis shared on X.com in November 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 81 year old woman living in Shanghai, CHINA with Stage 4 Melanoma, reports after 3 months! Most cancer is gone.
Want to hear my success story from CHINA? STORY: 81 year old woman living in Shanghai, CHINA with Stage 4 Melanoma In early August 2025 she started: Ivermectin 1mg/kg/day Fenbendazole 1000mg/day From patient's family: "We're seeing great remission of the tumor on her neck, a shrinkage of about 70%...we're very thrilled over the progress and very grateful for your services!" "I'm happy to report back that my aunt's stage 4 melanoma has been in remission since she started the protocol that you provided back in August 12"


Valerie Anne Smith posted on X.com in October 2025:

"Topical Ivermectin Will Completely Heal Skin Cancer...The Lesion Will Change, Get Smaller & Fall Off Completely." "You Can Literally Use It For Any Inflammatory Or Autoimmune Skin Condition." "It Comes As A 1% Prescribed Cream Or Buy The Over The Counter 1.87% 'Horse Paste.' Ivermectin is an antiparasitic drug with anti-inflammatory, anti-viral, anti-bacterial & anti-tumor effects.

Topical Ivermectin has fantastic applications in the dermatology world because it heals the skin microbiome of parasites, bacteria, toxins & pathogens. While healing the gut microbiome is paramount from within by using nutrition to detoxify & heal deficiencies...topical Ivermectin cream works to heal the stubborn epidermis & dermis layers of the skin that may not respond to internal healing completely. Topical Ivermectin Has Shown To Be Effective At Healing The Following Skin Conditions: Basal Cell Carcinoma Squamous Cell Carcinoma Melanoma Cystic Acne Ringworm Scabies Demodex Skin Mites Perioral Dermatitis Pityrosporum Folliculitis Hookworms Lice Moles Warts Skin Tags Ringworm Candida Athlete's Foot Rosacea Eczema Psoriasis How To Use... Apply a pea sized or pencil eraser sized amount twice per day onto the area of concern. Purchasing Topical Ivermectin... Prescription: 1% Ivermectin Cream or Gel prescribed by your healthcare provider. Public Purchase: 1.87% Ivermectin Paste can be purchased in person at any veterinary or farm store. And it can be ordered online from many retail establishments such as Amazon. 👇Ivermectin Paste For Melanoma👇 frontiersin.org/journals/oncol 👇Ivermectin Clears Skin Cancers👇 pmc.ncbi.nlm.nih.gov/articles/PMC75 👇Ivermectin Use In Dermatology👇 pmc.ncbi.nlm.nih.gov/articles/PMC83 Speaker: Dr William Makis, MD


Case 12 - 2025: 69 year old man from Peru with Stage 4 Melanoma (Anorectal)

Dr William Makis shared on X.com in October 2025:

IVERMECTIN and MEBENDAZOLE Testimonial - 69 year old man from Peru with Stage 4 Melanoma (Anorectal) reports after 4 months - dramatic improvement in quality of life! One of the most incredible testimonials I have, all the way from PERU! STORY: 69 year old man from Peru with Stage 4 Melanoma (Anorectal). He was given a prognosis of 3-6 months In late May 2025 he started: Ivermectin Mebendazole (high dose) He had one immunotherapy treatment (Nivolumab) which he didn't tolerate due to side effects. RESULT after 4 months (shouldn't be alive): Not only was his tumor “visibly reduced in size” but the clinical improvements have been nothing short of miraculous. "Since mid-July, he has completely stopped using any pain medications or laxatives. He now experiences no pain and is able to have regular bowel movements without discomfort, with normal stool consistency." "General Condition and Improvement: Previously, my father was bedridden — he only got up to use the restroom and required assistance to walk. He wore adult diapers and had no appetite. Since mid-July, however, he has shown remarkable improvement: He has regained weight. His appetite has returned. No longer uses diapers. Walks independently. Even drives his car on his own without any issues. He reports no anal pain. NO ONCOLOGIST. NO CHEMO. NO RADIATION. NO IMMUNOTHERAPY (couldn't tolerate it).


Case 11 - 2025: 59 year old Michigan woman with Skin Cancer (SCC and BCC)

Shared by Dr William Makis (X.com) in October 2025:

IVERMECTIN and MEBENDAZOLE Testimonial - 59 year old Michigan woman with Skin Cancer (SCC and BCC) sees major improvements after 4 months
Skin cancer can be very frustrating as it comes back again and again and again. Do you know how modern Oncology deals with that? Cut. Cut. Cut. That's it. NOT if you are a member of the world's largest Ivermectin Cancer Clientele. NOT if you've come to me! STORY: 59 year old Michigan woman with Skin Cancer (SCC and BCC) In early March 2025 she started: Ivermectin 1mg/kg/day Fenbendazole 1000mg/day, then switched to Mebendazole 1000mg/day End of June 2025, annual scan revealed NO skin cancer recurrence. " (the dermatologist) Her yearly exam has always resulted in one or several areas being frozen or surgically removed, so having no action required was a feeling of success".


Case 10 - 2025: Metastatic Melanoma NRAS Variant, age 69, Male

Shared by Ben Fen in August 2025:

This Case Report of PC, as told by his wife, documents the case of a 69-year-old male, with Stage 4 metastatic melanoma who achieved a complete metabolic response. PC initiated treatment with fenbendazole, resulting in a significant partial response, including the resolution of multiple metastatic sites. The subsequent addition of combination immunotherapy (Nivolumab/Relatlimab) led to the complete resolution of all detectable disease. This case highlights a successful therapeutic sequence, demonstrating the profound anti-neoplastic effects of fenbendazole and its synergy with checkpoint inhibitors in achieving a durable, cancer-free outcome.

Clinical Timeline: Diagnosis, Treatment, and Response

Jan 2023: Diagnosis: Stage 4 metastatic melanoma confirmed. Widespread disease in clavicle, aorta, abdomen, leg, mediastinum, and a suspicious brain lesion.

Initiated Fenbendazole: 222 mg daily. PC begins self-directed therapy.

May 2024: PET-CT: Resolution of clavicular and mediastinal metastases. Persistent para-aortic disease (SUV max 7.04). Unremarkable brain CT.

Fenbendazole 222 mg daily. Significant partial response to fenbendazole monotherapy.

June 8, 2024: Genetic testing confirmed NRAS mutation, CDKN2A gene )p.M53l variant).

June 10, 2024: Blood Panel: Transient elevation of liver enzymes (ALT/AST).

Fenbendazole 222 mg daily. Liver enzyme elevation likely due to tumor lysis; therapy continued.

June 20, 2024: Dose Adjustment: Fenbendazole increased to 444 mg daily (222 mg twice per day). Fenbendazole Dose Escalation. Dose increased to drive further therapeutic response.

Sept 17, 2024: PET-CT: Resolution of cutaneous leg lesion. Further reduction in para-aortic node (SUV max 5.89). No new disease.

Fenbendazole 444 mg daily. Continued favorable response.

Blood Panel: Liver enzymes returned to normal range.
Fenbendazole 444 mg daily. Normalization confirms the transient nature of the enzyme elevation, ruling out hepatotoxicity.

Sept 20, 2024: Immunotherapy Initiated: Began combination therapy with Nivolumab/Relatlimab (monthly infusions).

Immunotherapy Introduced. Standard-of-care immunotherapy added to consolidate gains.

Jan 10, 2025: CT & PET Scans: No nodal or metastatic disease detected. Para-aortic node no longer avid (SUV max 2.3). Clear brain scan.

Immunotherapy complete. Complete Metabolic Response Achieved.

May 15, 2025: Follow-up: PC is active, in excellent health, and remains cancer-free. Immunotherapy-induced colitis fully resolved. No active cancer treatment.

Durable Complete Response.

Case Presentation and Clinical Course

Initial Diagnosis and Fenbendazole Monotherapy: In January 2023, a 69-year-old male (PC) with a 35-year history of surgically managed melanomas was diagnosed with Stage 4 metastatic disease. PET-CT imaging confirmed extensive metastases involving the left supraclavicular fossa, mediastinal lymph nodes, para-aortic arch, abdomen, a cutaneous leg lesion, and a brain lesion of high concern. PC commenced self-administered fenbendazole at 222 mg daily. Over the next 16 months, he achieved a significant partial response on fenbendazole monotherapy. A PET-CT in May 2024 confirmed the complete resolution of metastases in the left supraclavicular fossa and mediastinal nodal stations.

Dose Escalation of Fenbendazole and Continued Response: In June 2024, a routine blood panel revealed a transient elevation in liver enzymes (ALT/AST). This was interpreted as a consequence of tumor lysis rather than drug toxicity. The fenbendazole dose was confidently increased to 444 mg daily. By September 2024, follow-up imaging demonstrated further disease regression, including resolution of the cutaneous leg lesion and a decrease in the metabolic activity of the remaining para-aortic lymph node (SUV max reduced from 7.04 to 5.89). Concurrently, his liver enzymes had normalized, validating the decision to continue and escalate the fenbendazole dose.

Introduction of Immunotherapy and Complete Response: With the majority of the disease burden eliminated by fenbendazole, combination immunotherapy (Nivolumab/Relatlimab) was introduced in September 2024 to target the residual disease. PC experienced a significant adverse event of immunotherapy-induced colitis, which persisted for approximately eight months before resolving. Follow-up scans in January 2025 revealed a complete metabolic response. All evidence of nodal or metastatic melanoma was absent. The metabolic activity in the previously persistent para-aortic lymph node had fallen to background levels (SUV max 2.3). As of May 2025, PC remains in excellent health, active, and cancer-free.

Conclusions: The Foundational Role of Fenbendazole

The clinical timeline establishes that fenbendazole monotherapy was responsible for the substantial initial tumor debulking. By the time immunotherapy was introduced, the majority of the metastatic burden had resolved, indicating fenbendazole acted as the primary therapeutic agent in this case. This initial response likely created a more favorable tumor microenvironment for immunotherapy. By inducing immunogenic cell death through mechanisms such as microtubule disruption, fenbendazole enhanced the presentation of tumor neoantigens, effectively "priming" the remaining disease for a robust and complete response to checkpoint inhibition.

Tumor Lysis as the Potential Cause of Transient Liver Enzyme Elevation

The transient elevation of liver enzymes is attributed to the metabolic stress of processing significant tumor lysis, a phenomenon observed in other cases of effective fenbendazole treatment. The resolution of the transaminitis (liver enzyme fluctuation), even after a fenbendazole dose escalation, coincided directly with the reduction in overall tumor burden. This temporal relationship suggests that the enzymatic rise was a consequence of therapeutic efficacy, not drug-induced liver injury. The return of AST/ALT to within normal limits despite continued fenbendazole administration supports the assertion as well.

This case documents a complete and durable metabolic response in a patient with advanced metastatic melanoma. A sequential treatment protocol, initiating with fenbendazole to debulk the tumor followed by consolidation immunotherapy, proved to be a highly effective strategy. This outcome underscores the potent anti-neoplastic capability of fenbendazole and its synergistic potential with modern immunotherapies.

PC’s wife reports that he is presently a “box of birds” after coming through this experience in successfully eradicating his cancer.


Case 9: Ivermectin & Fenbendazole Testimonial - Stage 4 Malignant Melanoma
  • Source: https://t.co/WGllfQFysg
  • Description: Posted on March 29, 2025, by
    @MakisMD
    , this highlights an Australian man with Stage 4 malignant melanoma with metastases to multiple sites. He reportedly achieved a "cancer-free" status after 12 months using ivermectin and fenbendazole.

Case 8: Stage 4 melanoma with mets to lymph nodes

Shared by DavidCarl (X/Twitter):

"As I’ve told you, my wife had stage 4 melanoma with mets to lymph nodes. She started taking ivermectin before you released your protocols, 1mg/kg. Weeks later you published your protocols and I bumped her to 2mg/kg. I added 444 mg of fenbendazole. Her last pet scan was approximately 6 months where she was cancer free. Her oncologist was all smiles, but I never told him I was giving her the protocol. She continues to take .5mg/kg of ivermectin 6x week and 3x week of 444 mg fenbendazole. She was taking immunotherapy for about a year before I read about ivermectin. Her lesions were having moderate response to the immunotherapy per pet scans. After putting her on ivermectin, 45 days later with a pet scan she presented cancer free. We were blown away. I almost cried. Doctor this is the hope you’ve given us. Your stories continue to give my wife confidence. It is like a big dark cloud we lived with was lifted."


Case 7: Stage 3B Melanoma with liver failure

Shared by Dr William Makis (X/Twitter) - February 2025:

IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial:

FROM THE BRINK OF DEATH - Stage 4 Melanoma patient with extensive liver metastases given 2-3 days to live! Survives and most metastases are gone! 

If you only read 1 of my testimonials EVER, make it this one.  Canadian patient had Stage 3B Melanoma 5 years prior. In Dec.2024, he presented to emergency in liver failure.
"He was told (by an Oncologist) Dec.2nd that he had 2-3 days to live and was in liver failure as his entire liver was consumed with tumors". 

(Diagnosis: Stage 4 Melanoma recurrence with extensive liver metastases & liver failure) “The only thing he (Oncologist) could suggest to try was Bractovi and Mektovi but has never given it to anyone with their liver in such bad shape – we are told that it is completely taken over with both cystic and solid lesions. Against our belief we were faced with a ‘try or die….” "He was given 1-2% chance with Braftovi/Mektovi so started that Dec.3rd" "I reached out to you shortly thereafter and started your protocol. The CT results from Jan.30th (2025) that I am sending you show significant regression or complete resolution!!!" 

Braftovi/Mektovi - 59 days 
Ivermectin - 43 days 
Mebendazole - 38 days 
Fenben - 28 days MAKIS IVERMECTIN CLINIC PROTOCOL Implemented: 
Ivermectin 1mg/kg/day (43 days) 
Mebendazole 400mg/day (38 days) 
Fenbendazole 444mg/day (28 days)

Yes, you read that correctly. This is what's called "weighing the risks and benefits".

CT RESULTS: "All previously detected hepatic lesions have markedly regressed or resolved." "Excellent response to the interval instituted treatment regime, where there has been marked regression of the metastatic liver disease with associated significant reduction in the associated hepatomegaly. "There has been significant regression of the metastatic lymphadenopathy of the root of the small bowel mesentery" "there has been complete resolution of the underlying anasarca and ascites" "There are presently no signs of acute intra-abdominal/pelvic process observed" ----- My Take… Do you know what is probably the single most frustrating question I get every day? “Is Fenbendazole safe? My doctor told me it will damage my liver!” "My doctor told me Fenbendazole will destroy my liver" Let me summarize: Stage 4 Melanoma patient with extensive liver metastases told he had 2-3 days left to live... in LIVER FAILURE...
Implemented a Protocol with Ivermectin, Fenbendazole and Mebendazole! 

And is alive 2 months later with all metastases either shrunk or gone! FROM THE BRINK OF DEATH… If anyone ever tells you that Fenbendazole or Mebendazole will damage your liver, know that they are lying to you, and if you want to, show them this story!







Case 6: Basal Cell Carcinoma (BCC)

In this December 2024 case report published by Canadian Oncologist Dr. William Makis, we note the pictorial resolution of basal cell cancer [BCC] to the point that the patient may have to cancel his appointment for a planned surgical removal. One cannot surgically remove a basal cell cancer [BCC] that no longer exists.

This gentleman reports he is a long-time reader of Dr. Makis and was particularly interested in his reports of Fenbendazole and Ivermectin. He contracted basal cell cancer on his face in February or March of 2024, and did what most of us would do - he booked an appointment with his GP in June 2024, apparently the first available.

The soonest he could get scheduled for the Dermatology referral was sometime in November. Having nothing to lose, he decided to apply Fenbendazole paste per the articles he had previously read, and to his pleasant surprise the persistent non-healing skin cancer of seven months began to shrink in size.

FenBen Treatment from September 25 through October 28, 2024

By the time of his November Dermatology appointment, there was very little to biopsy, yet it was done. He reports the Dermatologist was not the least bit interested in his tumor shrinkage with the Fenbendazole paste. Instead, the Dermatologist booked him for a tumor removal appointment three months later in February 2025.

The patient continued to apply the paste for the next month following the November biopsy, and here is what the BCC looked like as of December 6, 2024.


Result of FenBen Topical Treatment from September 25 through December 6, 2024

He writes,

“I’m still treating it once a day with Safeguard 10% Fenbendazole and it seems to still be improving. So I’m undecided about whether I need to have anything removed. I guess I’ll see how it goes over the next while. Maybe it’s deep into the tissue despite having improved the surface cells. No idea.”

Dr. Makis writes in response that patients who take matters into their own hands seem to do better.


Case 5:

source: https://substack.com/home/post/p-155091883


Case 4: Melanoma (Skin Cancer)

Shared by Dr William Makis (X/Twitter) - Last Edited: October 2024:

FENBENDAZOLE Testimonial in Stage 4 Melanoma Cancer patient - didn't listen to Oncologist's advice to stop Fenben, and is now cancer free.

There is a key lesson here. The Oncologist gave the opposite advice of what was good for the patient. That's because the Oncologist was following Cancer Guidelines set by Big Pharma (like Pfizer). If this patient had followed his Oncologist’s advice and stopped the Fenbendazole, he would still have active Stage 4 melanoma metastases with a much worse prognosis. Maybe he'd already be dead. How do you know if you have a good Oncologist? Ask them how many COVID-19 Vaccines they took! The only correct answer is "0".



Case 3: May, 2022 - Squamous Cell Carcinoma

In September 2021, I went to the cancer clinic to get my second PET scan done after receiving the news in March 2021 that I have been diagnosed with cancer, and learnt that day that my tumor has shrunk to half the size it first was. There were still signs of lymph nodes increasing or being classified as unknown results. I continued the use of the fenben protocol along with a whole bunch of other supplements to take on a daily basis, as within 5 months results improved in comparison to a whole year of fighting off the protocol before with little to non improvement in results. I strongly believe in this protocol and in case you wondered – I am not on any chemotherapy/radiation/immunotherapy or any other western medicine use – this is a full on natural and holistic journey I went on, and I am happy to share my current protocol with all cancer patients out there:
  • Serrapeptase (at midnight)
  • Vit D & K2, Tudca 500mg, Graviola 1ml (on an empty stomach)
  • Varies supplementation with breakfast (like Vit C & B complex, probiotics, fish oil, curcumin, etc. along with fenben 888mg)
  • Multi-vitamin, turkey tail extract, fenben 888mg, and B17 apricot seed (with dinner)
  • Some more other supplements just before bed (like magnesium, Vit C, Graviola, high dose of melatonin, coffee enemas, etc)
  • Detox baths (1 x week)
  • Frequency music (before bed designed to kill cancer cells)
  • Mainly following a plant-based diet
  • Protein intake is limited to certain meats
  • Fresh whole foods/vegetables
  • Healthy fats only
I trust that this protocol I am following will guide a lot of people out of their state – just belief and trust the process along with the support from others who have been through this before. Good luck.

Case 2: October, 2022

In February and March of this year I was diagnosed with stage four melanoma. It had metastasized to my brain, lymph nodes, right lung, adrenal gland and right hip. My daughter pointed me to Joe’s story and this site. I started taking the fenbendazole protocol even before my oncologist gave me her treatment plan using Immuno therapy. The oncologist said that it had about a 30% success rate but not to expect any great results on the first scan after 4 treatments.

I had a PET scan last week and the results were almost too good to be true. Cancer basically gone. The tumor in my right lung had shrunk to less than half the size it was on the first PET scan. The uptake on that tumor decreased from 19.9 to 2.6. I was told by her that an uptake of less than 4.0 is no longer considered as cancerous.

I have been on the fenbendazole protocol for 166 days now. I received 4 immunotherapy injections using 2 different drugs. I can’t say for sure what definitively gave me these great results. Draw your own conclusions but I think the fenbendazole was largely responsible for the great results.

Case 1: January, 2022

At first me and my partner were unsure about trying alternative treatments in addition to the radiation my partner receives. With the help from a holistic healer and referrals from a couple of people in our community, we found out about the fenbendazole protocol and started to add the protocol along with a few other supplements to my partner’s daily intake/routine to aid in fighting the skin cancer on his neck.

24. Throat cancer

Refer to "Head and Neck" Cancer.

25. Thymus cancer

Case 2: 35 year old California man with Thymic Carcinoma

William Makis posted on (X/Twitter) in August 2026:

IVERMECTIN, FENBENDAZOLE and CBD Testimonial in Turbo Cancer - 35 year old California man with Thymic Carcinoma (after 3 COVID-19 jabs) reports after 12 months: tumors shrinking! No one else has Ivermectin in Thymic Carcinoma success stories! STORY: 35 year old California man with Thymic Carcinoma that developed after 3 COVID-19 Vaccines. In June 2025 he started: Ivermectin 1mg/kg/day Fenbendazole 1500mg/day CBD Oil 100mg/day Results after 12 months: "doctors feel his cancer is getting better and in other places stable" "Thymic carcinoma is a rare, aggressive cancer that starts in the epithelial cells of the thymus gland in the upper chest. Unlike slower-growing thymomas, thymic carcinomas grow quickly, invade nearby tissues (like the lungs or blood vessels), and are harder to treat" Pfizer and Moderna COVID-19 Vaccines cause very aggressive cancers called "Turbo Cancer" that often shows up at Stage 4 in young people. They typically don't respond to conventional Oncology treatments but will often respond to repurposed drugs like Ivermectin, Mebendazole and Fenbendazole.


Case 1: October, 2022

Condition: Thymus cancer

Was diagnosed with Thymic Carcinoma 06/2022. Just finished week 8 of 12 week chemotherapy. I have been taking fenbendazole, curcumin, vit D & K, and CBD oil. We will do another PET scan in October and I fully expect the tumors to be completely gone or greatly reduced. Will update with the results asap. Blessings to all.

26. Thyroid Cancer (3 cases)


27. Turbo Cancer (Aggressive Cancer)

Experts are seeing a puzzling rise in cancer in people under 50 that appears biologically different from late-onset cancers. While some claim cancer rates have been rising for decades and attribute the increase to sugary drinks, lifestyle, and sleep disruptions, others say mRNA COVID-19 vaccines have caused an emergence of “turbo cancers”—and U.S. regulatory agencies have not addressed the ever-growing problem.  


28. Testicular Cancer

Case 1 - 2025: 51 year old UK man with Stage 4 Mixed Germ Cell Testicular Cancer metastatic to the lung

Dr William Makis shared on X (November 2025):

IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial - 51 year old UK man with Stage 4 Mixed Germ Cell Testicular Cancer metastatic to the lung reports after 6 months! Surgeon is absolutely shocked.
This is a World's First for this cancer type 51 year old UK man with Stage 4 Mixed Germ Cell Testicular Cancer metastatic to the lung In Mid April 2025 he started: Ivermectin 1.5m/kg/day Fenbendazole 1332mg + Mebendazole 200mg/day The surgical report is after 4 months. Aug.16, 2025 Surgery: left-sided thoracoscopic pulmonary residual mass resection: “The lung lesion was purely necrotic…the resected lymph nodes only contained anthracosis but again, no cancer cells” “Excellent treatment response with a pathologic complete remission” From the patient: "I have had an excellent prognosis from my recent cancer journey!" "I needn't have had the lung resection after all (exact words from Oncologist) as the 1.5cm solid mass which was residual after chemo ended 20/06/25 had completely turned to mush when examined during surgery on 16/08/25. "I have no doubt that your protocol which I have taken since April of this year is a major factor in my recovery" "Myself and my family, can't thank you and your team enough for giving us the extra belief and strength needed to fight this awful disease"

29. Uterine Cancer (7 cases)

Uterine cancer, also known as womb cancer, includes two types of cancer that develop from the tissues of the uterus. Endometrial cancer forms from the lining of the uterus, and uterine sarcoma forms from the muscles or support tissue of the uterus.

Refer to "Endometrial Cancer" case reports above.

30. Others

Case 2 - 2025: 65 year old Ontario Man with Stage 4 Angiosarcoma with bone marrow infiltration

Dr William Makis shared on X (November 2025):

IVERMECTIN and FENBENDAZOLE Testimonial - 65 year old Ontario Man with Stage 4 Angiosarcoma with bone marrow infiltration reports after 5 months.
Another success story and a happy Oncologist! 65 year old Ontario Man with Stage 4 Angiosarcoma with bone marrow infiltration In April 25, 2025 he started taking Ivermectin 1mg/kg In May 9, 2025 he started taking Fenbendazole 1000mg/day Results after 5 months: "The doctor said in order for his count to be where it is, means the bone marrow is healing" "Oncologist is very pleased and quite surprised with his results. Most recent visit shows no signs of cancer and bloodwork is good" "We are quite pleased with his results and will continue with your treatment" "We can't thank you enough for the work you are doing".


Case 1: 57 year old SLOVENIA man with a rare Stage 4 PECOMA* (Abdominal)

*Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms that arise from abnormal perivascular cells, expressing both melanocytic and smooth muscle markers. They can occur anywhere, commonly in the uterus, kidney, or gastrointestinal tract.

Dr William Makis shared on X.com in March 2026: 

IVERMECTIN and FENBENDAZOLE Testimonial - 57 year old SLOVENIA man with a rare Stage 4 PECOMA (Abdominal) reports after 3 months: Tumors shrinking! STORY: 57 year old SLOVENIA man with a rare Stage 4 PECOMA (Abdominal) For this patient, 3 months of Ivermectin 30mg + Fenbendazole 888mg + conventional Oncology therapy was not sufficient and his disease progressed. However, when he increased the dosing to Ivermectin 1.5mg/kg + Fenbendazole 1500mg + conventional therapy (Doxorubucin - has great synergy with Ivermectin and Fenbendazole although it wasn’t the Oncologist’s first choice), suddenly after another 3 months we see dramatic tumor shrinkage for the first time! Cancer Management is NOT easy, even though Ivermectin is so popular, everyone wants to treat cancer now! Seriously, everyone is a Cancer Expert these days! But what do you do when things get difficult? You can't put your life in the hands of amateurs.

Discussion

The compilation of over 700 fenbendazole (FBZ), mebendazole and ivermectin case reports in this updated guide represents a compelling grassroots chronicle of hope amid the oncology landscape's persistent challenges. These narratives, drawn from diverse global sources including patient forums, social media testimonials, and clinician observations, underscore a growing patient-driven movement toward repurposed therapies.
 
At its core, this collection challenges the status quo by highlighting FBZ's accessibility—costing mere pennies per dose—and its integration into multi-modal regimens that often complement, rather than replace, conventional treatments like chemotherapy or immunotherapy. 

Stories such as the 83-year-old woman's stage 4 breast cancer remission after eight months of 222 mg daily FBZ or the UK architect's wife's rapid clearance of high-grade B-cell non-Hodgkin lymphoma following a single chemo cycle plus FBZ evoke the serendipitous spirit of historical breakthroughs, reminiscent of penicillin's accidental discovery. Yet, as these accounts proliferate—fueled by viral X posts from advocates like Joe Tippens and Dr. William Makis—they also ignite critical discourse on evidence, equity, and ethics.

Dr William Makis posted this on X/Twitter in October 2025:

About 80% of cancer patients who try Ivermectin and Fenbendazole do so because their chemo, radiation, immunotherapy or other conventional treatments are NOT WORKING. Most are on their 3rd or 4th line of treatment and their cancer is PROGRESSING. Or they've been sent home to die by their incompetent or corrupt Oncologist who is not up to date on latest peer reviewed cancer research. These patients come to me for help BECAUSE what their Oncologists have done has not worked and now their Stage 1 and 2 cancer has turned to Stage 4 and continues to get worse. They are dying at the hands of their Oncologist. Then they seek out ALTERNATIVES. About 10% of those who try Ivermectin and Fenbendazole are at an early stage. Vast majority will also do their surgery or even chemo as well. But some will become cancer free and may not need surgery or chemo at that point. About 10% of those who try Ivermectin and Fenbendazole do so because they can't have chemo due to prior severe side effects, or they make an informed decision not to. But when they make a decision not to, they were not going to take chemo under any circumstances (maybe they watched their loved one die from chemo, maybe their fear is too strong, maybe their body is too weak). Their decision has nothing to do with Ivermectin or Fenbendazole itself. If Ivermectin didn't exist, they would have made the same exact decision.

Dr John Campbell posted recent related videos on YouTube (Nov 2025):
  1. Dr. Campbell reviewed a May 2025 case series involving three self-treated patients with breast cancer, prostate cancer, and melanoma, which is among the few peer-reviewed human reports in this area. Although the number of cases is small and anecdotal, Dr. Campbell emphasized the importance of such case observations, drawing a parallel to the historical discovery of scurvy treatment by Dr. James Lind. These observational case studies can provide critical early insights that pave the way for further clinical research and potential breakthroughs in treatment. (YouTube)
  2. Dr. Campbell received over 4,000 comments, with many individuals sharing their personal success stories using fenbendazole or ivermectin to treat cancer within their families, friends, and colleagues. These testimonials reflect a growing interest and anecdotal evidence in the use of these antiparasitic drugs as alternative or complementary cancer therapies, although formal clinical validation is still needed. This widespread feedback highlights the community’s engagement and the potential relevance of repurposed drugs in cancer care. (YouTube)
  3. Tennessee, Arkansas, Louisiana, Idaho, Texas, Florida maybe soon are the States where ivermectin may be bought over the counter. GOVERNOR RON DESANTIS AND FIRST LADY CASEY DESANTIS ANNOUNCE $60 MILLION FUNDING OPPORTUNITY FOR INNOVATIVE CANCER RESEARCH ON WORLD CANCER RESEARCH DAY. Further, priority will be given to projects that focus on nutrition, and the repurposing of generic drugs such as ivermectin for cancer treatment. (YouTube)
Jane McLelland posted this on Substack in March 2026:

Cancer isn’t a single target—it’s a resilient, rewiring system with backups at every turn.
  1. Escape Routes Remain Open: If you are familiar with my Metro Map, it shows how tumours hijack multiple fuels (glycolysis for glucose, glutamine addiction, fat and cholesterol pathways) and signals (growth factors like EGFR, downstream cascades like RAS/PI3K-AKT/STAT3, inflammation drivers like NF-κB and HIF-1α, microenvironment support). Fenbendazole and ivermectin might disrupt microtubules and mitochondria—like damaging a couple of power stations—but the tumor switches fuels, reroutes signals, or taps untouched lines. Key drivers stay active. Some people are lucky and this might be enough. But most won’t be.
  2. Mega-Dosing Doesn’t Magically Expand Impact: The thinking “if a little pressures it, mega will crush it” feels intuitive, but it doesn’t hold up. Higher doses don’t unlock new beneficial pathways—they amplify risks to your liver, kidneys, nerves, bone marrow, and blood counts. Toxicity can build subtly, and you may stress your body more than the tumor while major pathways go untargeted.
  3. Evidence Is Still Early and Indirect: We’re largely at case reports (some intriguing self-use stories in recent publications, often with confounders like concurrent treatments - because cocktails ultimately matter), and small observations. No large randomized human trials prove these alone reliably control or cure major cancers. Centres track rising mentions, but dosages vary widely, and standalone efficacy remains unproven. Anecdotes inspire, but they don’t establish clear cause-and-effect—especially when many combine with standard care.
Why I Advocate for the Multi-Pathway “Cocktail” Approach

I survived terminal cancer by mapping the full metabolic and signalling network and blocking multiple lines at once: starve fuels, jam growth signals, stress cells, limit adaptation. It’s engineering a comprehensive blockade—surround the tumor city and cut every major supply route you can.

  • Hit Multiple Fuels: Beyond mitochondrial stress from these two, layer in glucose control (metformin, guided low-glycaemic or intermittent feeding), glutamine restriction with supplements and drugs (e.g. niclosamide, EGCG), fat/cholesterol modulation.

  • Block Upstream Signals: Target receptors (RTKs), cascades (RAS/MEK/ERK, PI3K/AKT) — fenben and ivermectin offer limited upstream blockade on these signals.

  • Address Survival and Inflammation: Influence STAT3, NF-κB, mTOR, HIF-1α with other repurposed tools e.g. nifuroxazide, metformin and the under-appreciated antiparasitic niclosamide which has much broader anti-cancer effects than either fenbendazole/mebendazole or ivermectin. Niclosamide and has been on my Metro Map since I first published in 2018. Please investigate it!

  • Synergize with Standard Care: The most effective repurposing sensitises tumours to chemo, radiation, or immunotherapy, reduces resistance, and reshapes the microenvironment—not replaces the core treatments.

Anecdotal evidence, while profoundly humanizing, inherently carries limitations that temper enthusiasm. Survivorship bias is evident: This archive captures triumphs but omits the untold failures, spontaneous remissions, or confounding variables like concurrent therapies. For instance, many protocols blend FBZ with ivermectin, vitamin E, or curcumin, as in the Joe Tippens regimen, complicating attribution.
Recent X discussions amplify this, with posts celebrating "complete remissions" in stage IV colorectal and lung cancers yet rarely dissecting dropouts or toxicities. Preclinical data bolsters plausibility—FBZ's microtubule disruption and glycolysis inhibition show promise in models of breast, lung, and cervical cancers—but human translation lags. 

This evidentiary gap fuels ethical tensions. On one hand, FBZ embodies the "right to try" ethos, empowering underserved patients in low-resource settings where standard care is inaccessible—global cancer survival disparities persist, with stage IV rates under 20% in many regions.

Testimonials like the 60-year-old's prostate cancer PSA plunge from 196 to 0.16 after six months of FBZ plus ivermectin suggest adjunctive value, aligning with calls for compassionate-use trials. On the other, unchecked hype risks harm: Delaying proven interventions or self-dosing without monitoring (e.g., liver function tests) could exacerbate outcomes, as warned by oncology bodies. Regulatory inertia—exemplified by the UK oncologist's fear of professional repercussions—highlights systemic barriers.

Key Challenges and Opportunities for Advancement:
  • Evidentiary: No RCTs; reliance on cases with confounders. Opportunity: Phase I/II trials for bioavailability-enhanced formulations (e.g., nanoparticles).
  • Safety: Undocumented long-term human effects; interactions with therapies. Opportunity: Prospective registries tracking FBZ users for real-world data.
  • Access: Veterinary sourcing raises purity concerns. Opportunity: Policy shifts for "repurposed drug" fast-tracking, per EUCLID initiatives.
  • Equity: Hype benefits proponents; underserved voices underrepresented. Opportunity: Global collaborations for inclusive trials, integrating patient-reported outcomes.
Looking ahead, 2026's momentum—spurred by case series and advocacy—signals a pivotal juncture. As cancer incidence surges (projected 35% rise by 2050), repurposing low-cost agents like fenbendazole, mebendazole and ivermectin could democratize care if validated. Integrative oncology models, blending FBZ with precision medicine (e.g., targeting glycolysis in hypoxic tumors), hold synergistic promise. Researchers must prioritize: Fund pharmacokinetics studies, launch adaptive trials, and foster dialogue between patients, clinicians, and regulators. These stories are not endpoints but provocations—whispers demanding amplification through science. Until then, they remind us: In the face of uncertainty, courage and curiosity endure, but so must caution. 

Conclusion

In synthesizing the 700+ fenbendazole (FBZ) success stories chronicled in this updated edition, a tapestry emerges—not of unassailable cures, but of resilient human ingenuity confronting cancer's formidable shadows. These vignettes, spanning glioblastoma's relentless advance to colorectal's insidious spread, illuminate FBZ's role as a humble yet potent adjunct: disrupting microtubules, starving glycolytic tumors, and synergizing with immunotherapies in ways preclinical models increasingly validate. 

From the stage IV pancreatic patient's improbable 18-month remission on 444 mg daily FBZ plus berberine to the 72-year-old's ovarian cancer marker normalization after integrating it with Keytruda, the patterns are persuasive: Affordable, accessible, and often life-extending when woven into personalized protocols.

Critics may dismiss them as pseudoscience, low-quality data, or misinformation. However, these testimonials could represent just the tip of the iceberg—an emerging frontier that science is only beginning to explore.

Since these case reports lack a control arm, the biggest challenge remains identifying which patients will benefit from these treatments. That said, witnessing complete remissions in aggressive cancers with affordable repurposed drugs is a very encouraging sign.

While these anecdotal successes—supported by PET scan evidence and oncologists’ astonishment—suggest a paradigm shift in cancer management, they are observational and require robust, long-term clinical trials to confirm efficacy, safety, and optimal integration.

The absence of RCTs (randomised controlled trials), as echoed by oncology consensus, underscores the imperative for rigorous trials, bioavailability optimizations, and real-world registries to distill signal from anecdote. Ethical imperatives demand equity: Ensuring low-resource patients aren't sidelined by regulatory silos or hype's uneven reach. 

A 2026 peer-reviewed human study, published in Anticancer Research, a respected international peer-reviewed oncology journal, evaluated 197 cancer patients across multiple diagnoses — making it one of the largest peer-reviewed human studies to date examining the adjunctive use of Ivermectin and Mebendazole in cancer care.

It may take years for these anti-cancer agents to appear in mainstream medical journals, as bold results often provoke strong pushback. The most significant validation may come not from top journals but from a grassroots movement of patients and doctors with proven outcomes.

The momentum is undeniable—fenbendazole and ivermectin are not magic bullets. They may have a place as pieces in your larger anti-cancer strategy. But cancer rarely succumbs to one or two interventions, however determined.

True empowerment comes from multi-layered approach. Keep conversations open with professionals experienced in repurposing and metabolic approaches. You’re not alone—keep asking the hard questions, keep fighting smart, "as long as you try you cannot fail". 

Ultimately, these stories affirm that in medicine's grand narrative, patients are not passive recipients but co-authors. Armed with caution—consulting clinicians, tracking biomarkers, and prioritizing proven pillars—fenbendazole invites us to bridge desperation with discovery. May this compilation propel not just hope, but hastened science. For a more comprehensive understanding, it is worth exploring additional research studies and clinical trials. Always consult your healthcare provider before making any treatment decisions, as close monitoring and personalized care are essential.

Key Takeaways

  • Promising but Preliminary: Strong preclinical evidence and accumulating case reports highlight anti-cancer potential for ivermectin and fenbendazole, but definitive proof requires completed high-quality clinical trials.
  • Bridging the Gap: Case reports and real-world data offer valuable interim evidence, helping guide patients and researchers during the multi-year wait for large RCTs.
  • Off-label use is legal and widely accepted in medical practice. Off-label prescribing is a routine, legal, and evidence-based component of medical practice; however, it means that the drug has not been formally approved by the U.S. Food and Drug Administration for the specific indication discussed. As in all areas of active scientific inquiry, some recommendations may be debated, and regulatory agencies or professional organizations may adopt positions that differ from those presented here. (Read more)
  • For patients who have exhausted standard, evidence-based treatment options, there is a compelling case for institutions and regulatory bodies to formally evaluate repurposed drugs such as ivermectin and mebendazole within structured frameworks. This could include open-label clinical trials, compassionate-use programs, expanded-access pathways, or prospective patient registries. Establishing such mechanisms would allow oncologists and patients to explore these options transparently and ethically under medical supervision, while generating real-world data on safety and outcomes. 
  • Caution: Do not self-medicate. Always discuss any treatment with a trusted healthcare professional. Self-medication can carry serious risks, including liver toxicity and drug interactions. For the best outcomes, any treatment should be integrated into a personalized care plan that considers the whole person—not just the disease—and includes appropriate medical supervision and ongoing monitoring.


Disclaimers:
  • Statements on this website have not been evaluated by the Food and Drug Administration. The contents of this website is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis or treatment.
  • Please do not consider this guide as personal medical advice, but as a recommendation for use by professional providers. Consult with your doctor and discuss with her/him. Our aim here isn't to replace your doctors' advice. It is intended as a sharing of knowledge and information. Do take note that cancer is a continuous struggle between the immune system and the cancer cells. Cancer treatments are meant to assist the immune system in this battle. Any potential treatment—whether conventional or complementary—must be evaluated on a case-by-case basis, weigh both sides and with careful consideration of the benefit-risk ratio to ensure both safety and efficacy.
  • The case reports presented reflect the real-life experiences and opinions of other readers or users of the website. The experiences of those readers or users are personal to those particular readers/users and may not necessarily be representative of all readers/users. We do not claim, and you should not assume, that all other readers/users will have the same experiences. Do you own research (DYOR), consult with relevant medical professionals before attempting to self-treat for any condition.
  • Cancer care is a team effort with coordinated care across multiple healthcare specialties with the patient at the centre. Care should be supervised and coordinated by a primary healthcare provider. Patients with cancer should consult with their regular oncologist as well as an integrative provider/oncologist, in addition to their primary care provider and the supporting nurses, dieticians and other allied healthcare professionals.
  • Cancer treatment should be part of a multi-modal approach in order to provide the best possible outcome. Diet and lifestyle changes are meant to run alongside conventional treatment. They are complementary, not alternative. 
  • While the term 'alternative' might imply opposition to conventional oncology, we prefer 'complementary,' 'integrated,' or 'holistic'. These terms better reflect the role of these strategies as part of a personalised value-added menu of team effort strategies, ensuring the most effective and safe solutions for patients.
  • Integrating a repurposed drug doesn't mean rejecting modern medicine — It enhances it and offers a more comprehensive approach to wellness and healing. By combining conventional cancer management with root-cause resolution, this model creates a path to sustained recovery and resilience. 

Sources and References: 
  1. Fenbendazole and Cancer - at least 12 Anti-Cancer Mechanisms of Action.
  2. Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol.
  3. https://healnavigator.com/fenbendazole-cancer-success-stories-and-testimonials.
  4. https://www.fenbendazole.org/category/case-reports/ 
  5. https://fenbendazole.substack.com/
  6. Mebendazole vs fenbendazole for cancer
  7. Ivermectin vs Fenbendazole for Cancer
  8. Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types
  9. Ivermectin, Fenbendazole, and Mebendazole for Stage 4 Cancer: 300+ Case Reports Compilation
  10. Ivermectin Cancer Success Stories
  11. Top 30 Repurposed Drugs and Metabolic Interventions to Control Cancer
  12. Top 10 Cancer Fighting Supplements
  13. Joe Tippens Protocol Fenbendazole
  14. Ivermectin and Fenbendazole: Treating Turbo Cancer.
  15. Ivermectin: 15 Anti-cancer Mechanisms of Action.

Find Integrative Oncologists in USA, Mexico, Europe or Asia

While the potential anti-cancer properties of fenbendazole are intriguing, it’s crucial to approach with caution.

Consulting with an integrative healthcare expert is key to crafting a Fenbendazole protocol tailored to your unique health requirements. 

To find integrative oncologists, check out "find integrative oncologists".

Updated Joe Tippens Protocol

In 2016, Joe Tippens was diagnosed with non-small-cell lung cancer with extensive metastatic disease. At the advice of a veterinarian friend, he took Fenbendazole together with nanocurcumin, and three months after starting these drugs his PET scan was completely clear.

Below is a modified version of the Joe Tippens protocol, a synergistic combination of fenbendazole, ivermectin and nutraceuticals, updated based on the ivermectin and mebendazole based protocol published in the Journal of Orthomolecular Medicine (2024) and Journal of Anticancer Research (2026):
  • Ivermectin (25 mg/day, 6 days a week) or in the case of severe aggressive cancers up to 1mg/kg/day.
  • Mebendazole (250 mg/day, 6 days a week) or Fenbendazole, commonly taken at 300 mg for six days a week, with doses increasing to up to 1 gram in cases of aggressive cancers.
  • Most berberine and curcumin supplements have low oral bioavailability. UltraCur Curcumin Complex and Pure Encapsulations Berberine UltraSorb are specially formulated for optimal absorption.
  • Diet and Lifestyle: 
    • A 2026 study (American Association for Cancer Research), linked Ultra-Processed Foods to Reduced Survival after Cancer. Sugar, starch, saturated fat packed into ultra-processed food not only associated with obesity, diabetes, and heart disease, it also worsens cancer prognosis.
    • Another 2026 study published in The BMJ examined how everyday exposure to food preservatives influences cancer risk. The findings were clear — people who consumed more preservatives had higher rates of overall cancer and breast cancer. The findings support recommendations for consumers to favour freshly made, minimally processed foods.
    • Another 2026 findings published in Nature Communications, insulin resistance has been linked to a 25% higher risk of 12 different types of cancer. Insulin resistance is often caused by obesity and its associated chronic inflammation. Both diabetes and obesity are associated with a higher risk of cancer. 
    • Adopt a whole-food diet and avoid ultra-processed foods, as recommended by the BMJ 2024 guidelines. 
    • Eliminate sugar consumption as supported by the BMJ 2023 umbrella review, which recommends reducing free and added sugars to below 25 g/day and limiting sugar-sweetened beverages to less than one serving per week to reduce adverse health effects. 
    • Additionally, prioritise adequate sleep and effective stress management to support overall health.
*Notes:
  • Please note that this protocol now includes the vital Vitamin D addition, with the one day off for the fenbendazole administration. This protocol represents the most comprehensive and cutting edge repurposed drug and vitamin treatment approach to date.
  • Vitamin E: Removed from the protocol (Joe Tippens, July 22, 2020) due to interactions (e.g., with blood thinners).

FAQ

If you have questions to ask regarding this article: Ask AI Assistant.


Like and Follow us for more updates on X.com and Substack.

Ivermectin and mebendazole, both approved for human use, are now available in the U.S.

Researched and approved by Dr. Peter McCullough.
  • Prescribed by licensed medical professionals
  • Compounded and dispensed by a licensed US-based pharmacy
  • Approved for human use
Where to buy Ivermectin and Mebendazole Formula: Available on The Wellness Company's website. Here is the link: Ivermectin and Mebendazole.

Comments

Post a Comment

Labels

Show more

Archive

Show more

Popular posts from this blog

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

-
Image
Medically Reviewed by: Dr Frank Yap, MD | Written by:     OneDayMD Editorial Team | Last Updated:   September  2026 Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) has treated a large volume of cancer patients using repurposed drugs since 2023 and has documented outcomes publicly on Substack and X. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medica...
Read more

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2026)

-
Image
Medically Reviewed by: Dr Frank Yap, MD | Written by:     OneDayMD Editorial Team | Last Updated:   September  2026 If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories  and a recent peer-reviewed publication, " Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients : Results from a Prospective Observational Cohort ( Anticancer Research 2026 )" We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a s...
Read more

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

-
Image
Quick Summary: DMSO (Dimethyl Sulfoxide) is a naturally occurring compound with decades of research behind its use as an anti-inflammatory, analgesic, and cellular-protective agent. FDA-approved for interstitial cystitis, it has been used off-label by athletes, physicians, and patients for musculoskeletal injuries, chronic pain, wound healing, and more. This guide covers what DMSO is, how it works, the evidence for its key uses, safety considerations, dosing guidance, and where to find practitioners who use it. All off-label uses are experimental. Consult a qualified healthcare provider before use. A Patient Story: From Lung Transplant List to Clear CT Scans In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. “I d...
Read more

How to Get Ivermectin in the US: Pharmacies, Legal Status & State-by-State Access (2026)

-
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: August 2026 An updated, evidence-based guide to ivermectin's federal and state legal status, how to obtain a prescription, which states allow pharmacist-dispensed or OTC access, and a directory of pharmacies that fill ivermectin prescriptions in the US. Quick Answer (AI & Search Summary) Ivermectin is still classified federally as a prescription-only drug for human use. It has not been reclassified as OTC by the FDA. However, five states — Arkansas, Idaho, Louisiana, Tennessee, and Texas — have passed laws letting pharmacists dispense it without a doctor's prescription, and roughly half a dozen more have active bills. Everywhere else, you need a prescription from a doctor, urgent care provider, or telehealth service. Individual pharmacists retain the right to decline to dispense or stock it even where state law allows it. Table of Contents Current Legal Status (Federal & State) State-by-...
Read more

Fenbendazole, Ivermectin and Mebendazole for Cancer: Case Series of 760+ Case Reports (September 2026 Update)

-
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: August 2026 Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories (130 cases) Brain Cancer (including Glioblastoma) (135 cases) Bladder Cancer Success Stories  (including kidney cancer) (37 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (85 cases) Esophageal and Stomach cancer (23 cases) Endometrial Cancer (13 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer )  Head and Neck Cancer (17 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) Liver and Bile Duct Cancer  (Hepato-biliary system) (9 cases) Lung Cancer (62 cases) Leukemia (13 cases) Lymphoma (28 cases) Melanoma (refer to ...
Read more

Ivermectin, Fenbendazole and Mebendazole: A Peer-Reviewed Protocol for Cancer Treatment (2026 Update)

-
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: April 2026 In September 2024, a first-of-its-kind protocol utilizing ivermectin, fenbendazole, and mebendazole for cancer treatment was peer-reviewed and officially published in the Journal of Orthomolecular Medicine . Led by researchers Dr. Ilyes Baghli, Dr. Pierrick Martinez, and FLCCC's Dr. Paul Marik, the protocol applies antiparasitic drugs — originally developed to combat parasites — to cancer treatment, building on emerging preclinical and clinical evidence of their anticancer properties. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondrial-Stem C...
Read more

Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types (2026)

-
Image
Medically Reviewed by:  Dr Frank Yap, MD  | Written by:     OneDayMD Editorial Team | Last Updated:   August 2026 This article discusses dosage considerations and key factors related to the use of ivermectin in cancer treatment. Much of the publicly available information regarding ivermectin dosage is based on the standard dosing recommendations developed by Merck for the treatment of parasitic infections. These dosages are often cited without distinction from the higher or alternative dosing regimens that have been explored in cancer-related research. Dosages used for parasitic infections may not correspond to those investigated in oncology studies. Potential dosing strategies may vary depending on several factors, including the patient's body weight, cancer type, cancer stage and grade, overall health status, and liver function. ...
Read more

Ivermectin and Fenbendazole: Treating Turbo Cancer - Dr William Makis

-
Image
Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: July 30, 2026 Ivermectin Resources I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER. Editor's Note: Dr Makis proposes four distinct cancer protocols for using Ivermectin in cancer treatment, specifically for patients who have developed turbo cancer or aggressive cancers. These protocols, referred to as the “Dr. Makis Ivermectin Cancer Protocols,” are categorized based on dosage and the severity of the cancer. Update - Cautionary Remark by Dr Paul Marik ( Substack June 2026 ): Protocol (above and below) is a potentially toxic dosing protocol which we Do NOT Recommend Updated version An article and a video that go into depth: June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose Ivermectin and Cancer .  2025 - 2026 studies on ivermectin for cancer Clinical Hulscher et al -  Real-World Clinical Out...
Read more

Top Smart Glasses for the Visually Impaired (2026): eSight, Envision, OrCam & More

-
Image
Medically & Technically Reviewed by: OneDayMD Editorial Team | Originally Published: August 9, 2026 | Updated: September 2026 Quick Answer There is no single "best" smart glasses for visual impairment in 2026 — the right pick depends on how much usable vision remains. For low vision (residual central vision from macular degeneration, diabetic retinopathy, or Stargardt disease), medical-grade enhancers like eSight Go ($4,950) or Acesight VR digitally magnify and boost contrast. For blind or near-blind users, AI-interpretation glasses like Envision Glasses ($2,499), Ally Solos (from $399), or a clip-on OrCam MyEye 3 Pro (remaining dealer stock, $3,689–$4,490) read text and describe scenes aloud. The cheapest mainstream option is Meta's expanding AI-glasses lineup — Ray-Ban Meta, Meta Glasses (Adventurer/Fury), and Meta Glasses by Kylie — starting at $299, which isn't purpose-built for accessibility but has become a popular everyday alternative thanks t...
Read more

Best Fenbendazole Dosage for Humans: Safety, Side Effects and Efficacy Examined (2026)

-
Image
Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some fenbendazole advanced cancer success stories  (more than 500 case reports). Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different m...
Read more